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1. Abstract
Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous 
system resulting from a viral infection. JC virus (John Cunningham) is known to cause the 
demyelinating lesions in the white matter, but how oligodendrocyte death is really initiated during 
disease course is still under question. Besides the demyelination pathology, inflammation can be 
detected in the brain parenchyma of PML-patients. Though it is not established how the immune 
response including both activation of CD8+ cytotoxic T-lymphocytes and granzyme B release is 
involved in the pathogenesis. Therefore histochemical and immunohistochemical experiments were 
performed in order to get a better insight. The results of the investigations showed that the immune 
response is playing a minor role in PML and that hence induction of oligodendrocyte death is not 
likely to be initiated by to granzyme B release. In fact, no evidence was found that apoptosis is the 
deathly mechanism causing oligodendrocyte death. Therefore, other death inducing pathways were 
checked that would possibly give an explanation how CNS damage is caused. It was found that the 
key events of parthanatos, a rather recently described mechanism, were also detectable in the JC virus 
infected oligodendrocytes. These events included accumulation of poly(ADP-ribose) (PAR) in the 
cytosol and translocation of apoptosis inducing factor (AIF) out of the mitochondria into the nucleus, 
where it is capable of inducing DNA-fragmentation leading to cell death. In order to compare the 
results to other viral encephalitis diseases the same experiments performed on the PML-samples were 
also repeated on herpes simplex virus (HSV) encephalitis samples and cytomegalovirus (CMV) 
encephalitis samples. Interestingly, differences were found when comparing PML to HSV encephalitis 
and CMV encephalitis. In the latter ones the immune response seems to be more central and apoptosis 
was found to be the cell death inducing pathway and leading to CNS damage in those diseases.
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2. Zusammenfassung
Progressive multifokale Leukoenzephalopathie (PML) ist eine Virus-induzierte Erkrankung, die vor 
allem zu einer Schädigung des Zentralnervensystems führt. Durch diese Virusinfektion, die von einem 
Polyomavirus namens JC-Virus (John Cunningham) ausgeht, sterben die Oligodendrozyten in der 
weißen Substanz ab, wobei demyelinisierende Läsionen im Gehirn entstehen. Welcher Mechanismus 
zum Tod der Oligodendrozyten führt und somit hinter der Entstehung der Läsionen steht, ist bisher 
ungeklärt. Es ist allerdings bekannt, dass Patienten aufgrund des Krankheitsbildes von PML an einer 
Entzündung des Gehirns leiden. Diese Entzündung äußert sich darin, dass aktivierte CD8+
zytotoxische T-Lymphozyten in die weiße Substanz einwandern und dort möglicherweise Granzym B 
freisetzen, welches zur Aktivierung des Apoptosewegs führen kann. Um genauere Informationen über 
den Zusammenhang von Entzündungsreaktion und Oligodendrozytentod zu erfahren, wurden in dieser 
Arbeit histochemische und immunhistochemische Färbungen durchgeführt. Die Ergebnisse deuten 
darauf hin, dass die Immunantwort bei dieser Krankheit eine geringe Rolle spielt. Weiters wurden 
keine Indizien gefunden, die dafür sprechen, dass die Oligodendrozyten durch die Einleitung von 
Apoptose sterben. Aufgrund dieser Beobachtungen wurde nach anderen Zelltodwegen gesucht, die 
eine mögliche Rolle bei dieser Krankheit spielen könnten. Interessanterweise konnten die zentralen 
Ereignisse, die im erst kürzlich entdeckten Zelltodmechanismus namens Parthanatos auftreten, auch in 
den virusinfizierten Oligodendrozyten gefunden werden. Diese Ereignisse sind die Anlagerung von 
poly(ADP-Ribose) (PAR) im Cytosol, sowie der Transfer vom Apoptose-induzierenden Faktor (AIF) 
aus den Mitochondrien in den Zellkern. Im Zellkern kann AIF DNA-Fragmentierung auslösen, welche 
schließlich zum Zelltod führt. Um die Ergebnisse aus den Experimenten der PML-Proben mit anderen 
Virusenzephalitiden vergleichen zu können, wurden die gleichen Färbungen auch auf Proben aus 
Herpes simplex Virusenzephalitis (HSV) und Zytomegalovirusenzephalitis (CMV) wiederholt. Dabei 
wurde beobachtet, dass bei den HSV-Enzephalitiden sowie bei den CMV-Enzephalitiden das 
Immunsystem und dessen Aktivierung eine größere Rolle spielt als bei den PML-Fällen. Des Weiteren 
wurden bei HSV-Enzephalitis und bei CMV-Enzephalitis keine Anzeichen dafür gefunden, dass in 
diesen Erkrankungen Parthanatos als Zelltodmechanismus aktiviert wird. 
Mit diesen Ergebnissen konnte eine Erklärung für den Zelltod der Virus-infizierten Oligodendrozyten 
gefunden werden und es wurde gezeigt, dass unterschiedliche Mechanismen hinter der Entstehung des 
Schadens im Gehirn in den verschieden Virusencephalitiden stehen. 
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3. Introduction
3.1. Acute viral encephalitis
Encephalitis is an inflammatory process affecting the brain parenchyma. This inflammation is further 
linked to brain dysfunction. Generally, the triggering causes as well as the presentation of encephalitis 
are widely ranging. So, encephalitis can occur as an acute disease or a chronic disease. Since more 
information on acute viral encephalitis diseases is given later, chronic encephalitis is just shortly 
mentioned here. There are various different types described, but to give names, Rasmussen’s 
encephalitis like subacute sclerosing panencephalitis (a late complication of measles infection),
constitute to the group of chronic encephalitis. 
Another possible division of the different encephalitis diseases can be made according to the 
underlying causative factors. One possible group consists of encephalitis that results from an aberrant 
immune response, leading to development of autoimmune encephalitis. Examples for this kind of 
disease are acute disseminating encephalomyelitis (ADEM), acute hemorrhagic leukoencephalopathy 
(AHLE) and brain stem encephalitis. The other subtype can be termed infection-related encephalitis 
and might be the result of an infection with bacteria, viruses and parasites. The most prominent 
infectious agents are viruses which are likely to induce formation of acute viral encephalitis (Stone and 
Hawkins, 2007). The usual presentation of the disease is found to be fever, headache, altered 
consciousness, focal neurology and in some patients also seizures are occurring. If those symptoms are 
present an immediate start with treatment is beneficial for the outcome, since it is reducing the extent 
of brain damage and favoring survival (Steiner et al., 2005; Stone and Hawkins, 2007). Prominent 
viral encephalitis diseases are herpes simplex virus encephalitis (HSV), varicella-zoster virus 
encephalitis (VZV), Epstein-Barr virus encephalitis (EBV) as well as cytomegalovirus encephalitis 
(CMV). Another disease resulting from a viral infection of the central nervous system is progressive 
multifocal leukoencephalopathy (PML). PML is caused by the JC virus, which is present in 80% of the 
population, but is only being activated and leading to demyelination in the white matter in 
immunocompromised patient (Weissert, 2011). 
Since samples out of PML, CMV and HSV patients were most interesting and intensively studied in 
this project, more detailed information on these three diseases is given next. 
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3.1.1.Progressive multifocal leukoencephalopahty (PML)
Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous 
system (CNS). PML was first described in 1958 in immunosuppressed patients suffering from chronic 
lymphatic leukemia and Hodgkin’s disease (Astrom et al., 1958). In the early 1970s culturing of the 
virus isolated from a PML patient’s brain was succeeded and virus characterization was possible. It 
was found that a polyomavirus, called “JC” virus, named after the patient (John Cunningham) it was 
isolated from, was the underlying cause of the deadly disease (Padgett et al., 1971). Polyomaviruses 
are a family of double stranded DNA viruses. They have an icosahedral capsid which consists of three 
viral proteins, VP1, VP2 and VP3. Of these, VP1 is the most prominent protein to be recognized as 
viral particle by the immune system (Bag et al., 2010; Goldmann et al., 1999; Goldmann et al., 2000). 
PML is an opportunistic infectious disease (Berger and Houff, 2009; Weissert, 2011) and it mainly 
emerges in patients suffering from immunosuppression such as patients with lymphoid malignancies, 
organ transplant recipients and patients with AIDS (Wuthrich et al., 2006). The latter accounts for 
more than 80% of all PML cases (Koralnik et al., 2004) and up to 5% of AIDS patients were found to 
develop PML at the beginning of the AIDS epidemic (Berger et al., 1987). In 2005, PML was also 
seen to develop in multiple sclerosis and Crohn´s disease patients that were receiving 
immunomodulatory therapy, namely natalizumab, an mAb against CD49a (Kleinschmidt-Demasters 
and Tyler, 2005; Langer-Gould et al., 2005). In addition, in 2008, PML was seen to develop after 
treatment with rituximab, a mAb against CD20 (Carson et al., 2009). Interestingly in many countries 
up to 92% of the adults are seropositive for JC virus (Walker and Padgett, 1983). Although the virus is 
widely spread in the population, the incidence of PML is rather low. 
During development of PML three phases can be distinguished. The first phase is the primary 
infection with JC virus. This process is usually subclinical and asymptomatic and happens mostly 
during childhood (Bag et al., 2010; White and Khalili, 2011). In the following phase, the virus is 
thought to be latently present in the body. At which sites the virus usually resides is not totally clear, 
but it was detected in the kidney (Yogo et al., 1990), tonsils (Kato et al., 2004; Monaco et al., 1998), 
peripheral blood cells (Dorries et al., 1994), the bone marrow (Tan et al., 2009a) and also in the brain 
of individuals who weren’t suffering from PML (Mori et al., 1991). During the third and last phase, 
which is preferentially initiated in immunosuppressed individuals, the virus gets reactivated and 
appears within the CNS. How the dissemination to the brain is achieved is not really known, but 
hematogenous spreading is a possible mechanism (Bag et al., 2010; Weber, 2008). Also the timing 
when the virus enters the brain is not clear. It might be that the virus settles in the brain during primary 
infection, but it is also possible that JC virus spreads to the brain only during the reactivation process. 
Interestingly, two different types of JC virus have been identified until today and the differences of 
these virus types are seen in a key regulatory region, a noncoding control region (NCCR). This part of 
the genome seems to be of great importance as it regulates the viral replication as well as early and late 
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transcription events (White and Khalili, 2011). One of these virus types, the so called “archetypal” 
form, typified by the CY stain of JC virus, is predominantly present in the kidney, urine and sewage 
(Yogo et al., 1990), whereas the other form, known as the “prototypical form”, also “PML-type” of JC 
virus is found in PML and is also identified by a specific stain, called the Mad-1 stain (Frisque et al., 
1984). 
Knowing this, different options for development of PML are possible. One possibility is a genetic 
switch between the different virus types resulting in a kind of neuroadaptation (White and Khalili, 
2011) combined with hemorrhagic spreading to the brain. The other possibility would be a 
superinfection of both viruses, whereas only the “PML-type” JC virus manages to enter the brain. It 
can be easily seen that further investigations need to be done until all the questions on how JC virus is 
acting in the body and manages to infect the CNS are resolved. 
Figure 1 The typical features seen in patient's brains suffering from PML: a scan of paraffin-embedded section 
stained with luxol fast blue (Klüver-Barrera); b enlarged picture of a typical demyelinating white matter lesion 
resulting from oligodendrocyte death stained with luxol fast blue (40x magnification); c white matter lesion 
stained with an antibody targeting JC virus and it can be seen that the virus infected cells are located at the edge 
of the lesion (40x magnification); d JC virus infected oligodendrocyte showing a typical swollen shape (250x 
magnification); e JC virus infected oligodendrocyte undergoing cell death (250x magnification); f+g bizarre 
shaped JC virus containing astrocytes (250x magnification)
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The symptoms resulting from PML-development are mainly neurological. Patients show 
neuropsychological deficits, apraxia and dementia and suffer from visual deficits as well as motor 
problems (Berger and Major, 1999; Krupp et al., 1985; Weissert, 2011). As already indicated by the 
name, the disease course is progressive and therefore, unless treated, the patients remain in an 
immunocompromised state and die within months (Weissert, 2011). Pathological hallmarks of PML 
include virus containing oligodendrocytes which are located around demyelinating white matter 
lesions, bizarre shaped virus infected astrocytes in the centre of burnt out lesions and an inflammatory 
response consisting of lymphocytes and phagocytic macrophages (Richardson, Jr. and Webster, 1983)
(see Figure 1).
To avoid a fast death, an immediate reaction is necessary, but unfortunately there is no therapeutic 
agent available that is specifically harming the JC virus (Marshall and Major, 2010). Various trials are 
performed with drugs like nucleoside analogues, antipsychotics and cytokines. HIV-positive patients 
are treated with cART, an antiviral therapy, which is preventing HIV from replication and due to a 
higher immune response the outcome for PML is better as well. So far, only reconstitution of the host 
immune system seems to delay the deathly outcome of PML (Weissert, 2011).
Another disease that is sharing some features with PML and is also induced by the infection with JC 
virus is PML immune reconstitution inflammatory syndrome (IRIS). A difference between PML and 
PML-IRIS is found in the disease development, since PML develops during immunosuppression,
whereas PML-IRIS develops in cART treated HIV-patients during recovery of the immune system
(Weissert, 2011). Fortunately, unlike in PML, treatment with steroids is very effective in PML-IRIS 
(Tan et al., 2009b). Though PML and PML-IRIS are the most common forms of disease, there are 
other forms in which JC virus is identified to be the underlying cause. These diseases are referred to as 
JCV encephalopathy (Sandyk, 1983), JCV meningitis (Blake et al., 1992) and JCV granular cell 
neuronpathy (Koralnik et al., 2005) (Bag et al., 2010). 
3.1.2.Cytomegalovirus encephalitis (CMV)
Cytomegalovirus (CMV) is a member of the human herpesviridae family, whose members are known 
to be double stranded DNA viruses. Together with human herpesvirus-6 and -7, CMV is assigned to 
the subgroup of betaherpesvirinae. First contact with CMV is usually in the first 2 decades of life
(Zamora, 2011), whereas primary infection can also very often happen intrauterine, congenitally, 
perinatally or postnatally (James et al., 2009). It has been tried to erase CMV from the immune system 
through cell-mediated immunity or establishment of neutralizing antibodies. However, the virus seems 
to escape and remains latently in the body. CMV can reside in many different cells like hematopoietic 
progenitor cells, leukocytes, macrophages, peripheral blood cells, as well as endothelial cells and 
fibroblasts (Zamora, 2011). As already mentioned, CMV can infect endothelial cells, which are also 
located in the brain and the choroid plexus. Consequently, CMV can infect astrocytes near the 
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epithelium and can further use cerebrospinal fluid (CSF) to be transferred to the ependymal surfaces 
(James et al., 2009). 
Reactivation of JC virus is facilitated in immunocompromised individuals and it seems that the 
situation for CMV is the same, since it is also found to be mainly infectious in HIV positive patients 
(Quinnan, Jr. et al., 1984) or patients undergoing organ transplantations (Booss and Kim, 1989). Upon 
reactivation, CMV among others, can induce different diseases like CMV retinitis, colitis, pneumonitis 
and encephalitis (Rafailidis et al., 2008). In this thesis CMV encephalitis was particularly studied. 
Histopathologically, CMV encephalitis often shows inflammation around the ventricles. Due to 
spreading of the virus with CSF, in the parenchyma focal necrotic lesions as well as microglia nodules 
can be seen. Infected cells (either neurons or astrocytes) typically are enlarged and contain virus 
inclusions (see Figure 2). Due to the typical morphology, those cells are commonly known as “owl 
eyes” (Arribas et al., 1996) (Bestetti et al., 2001). 
Figure 2 Labeling of CMV infected cells with immunohistochemistry; A the typical “owl’s eyes” resulting from 
CMV infection can be easily distinguished from the non-infected cells, still there are also cells present that 
contain CMV and are not shaped in the typical “owl eye” fashion (250x magnification); a in the small insert 
picture an “owl’s eye” containing viral inclusions is shown (400x magnification)
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Patients with CMV spreading to the CNS usually present with fever, altered mental status, progressive 
confusion and sometimes impairment of memory and dementia. Rather rarely seen are patients 
suffering from seizures (Post et al., 1986). 
Most patients receive gancyclovir or foscarnet as antiviral therapy. Gancyclovir is a nucleoside 
analogue, whereas fornascet is a pyrophosphate analogue (Arribas et al., 1996) In some cases, patients 
are treated with a combination of both substances (Silva et al., 2010). 
3.1.3.Herpes simplex virus encephalitis (HSV)
Herpes simplex virus (HSV) is a double stranded DNA virus and constitutes to the family of human 
herpesviridae. There are two different types of HSV infectious for human, HSV type-1 and HSV type-
2. Both types are known as alphaherpesvirinae (Zamora, 2011). Generally, both HSV type-1 as well as 
HSV type-2 are neurotropic and are capable of inducing HSV encephalitis. Still incidence rates show 
that HSV type-1 is much more common than HSV type-2, which only accounts for 10% of HSV 
encephalitis (Stone and Hawkins, 2007). A difference between the two virus types is that HSV type-1 
is orally transmitted whereas HSV type-2 gets spread through genital transmission (Corey and Spear, 
1986). Primary infection is often subclinical and there are no symptoms detected. However, if there 
are effects seen, distinction between HSV type-1 and type-2 infection is possible. Manifestations of 
HSV type 1 infection are usually seen as fever blisters on the labia, whereas insults from HSV type 2 
infections are mainly presented on genital and perianal areas as painful vesicles and ulcers (Conrady et 
al., 2010) (Zamora, 2011). Though being a rather rare complication HSV can spread to the CNS and 
cause encephalitis. Since HSV is a neurotropic virus it preferentially infects neurons. For HSV type-1 
there is data available that confirms that this virus is entering the cell via binding to heparan sulfate 
proteoglycan and that the virus is residing in the neurons, which are used as hosts (Conrady et al., 
2010; Shieh and Spear, 1994; WuDunn and Spear, 1989). Accordingly the virus can spread via 
retrograde axonal transport and infect the nucleus of sensory ganglia (Shimeld et al., 2001). Like JC 
virus also HSV changes to a latent state after the primary infection and resides in the host’s sensory 
ganglia cells until it gets fully reactivated again (Bertke et al., 2009). The exact circumstances for viral 
reactivation are not totally understood, but it seems that stress to the host immune system is a 
beneficial factor for the virus’s reactivation. 
There can be found a lot of information on how the host immune system is acting in order to destroy 
HSV, but to completely understand the effects resulting from the immune response further 
investigations will be needed. Until today it became clear that HSV type-1 is triggering activation of 
the innate immune system through toll-like receptors (TLRs), which lead to type I interferon 
production, initiation of an inflammatory response and an according activation of the adaptive immune 
system. Nevertheless, remains the question, what factors lead to this extent of CNS pathology in HSV 
encephalitis. It is thought that due to extensive activation of the immune system the virus is eliminated 
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in the peripheral nervous system, but escapes to the CNS. Possible explanations are activation and 
release of toxic substances out of microglia and astrocytes which lead to CNS insult or the recruitment 
of activated leukocytes into the brain, which then release cytotoxic molecules and therefore induce cell 
death of infected cells (Conrady et al., 2010).
Results from the CNS damage can be seen as symptoms in the patients. Usually, HSV encephalitis is 
presented with headache, fever and an altered consciousness, whereas the resulting long-term 
consequences can be memory impairment, abnormalities in behavior and personality, epilepsy, 
anosmia (lack of perceiving odors) and dysphasia (McGrath et al., 1997; Stone and Hawkins, 2007). 
Interestingly there are differences in the presentation seen in adults compared to neonates and young 
children. In latter ones, HSV encephalitis is found to be more diffuse and in multiple locations 
(Batnitzky et al., 1986).
Fortunately, HSV encephalitis can be treated very successfully with acyclovir (Skoldenberg et al., 
1984; Whitley et al., 1986). Only if patients are infected with an acyclovir-resistant strand, they are 
treated with different drugs like cidofovir or foscarnet (Losada et al., 2002; Superti et al., 2008). 
Histological features, that are mostly found in adult HSV encephalitis brains are necrotic and 
hemorrhagic properties mainly located in the frontal or temporal lobe (Conrady et al., 2010; 
Kleinschmidt-Demasters et al., 2001). In ABC-studies it is shown that the main infected cells with 
HSV are neurons, astrocytes and oligodendrocytes, whereas the antigen can be found in the nucleus 
and the cytoplasm of those cells (Benjamin and Ray, 1975) (Kumanishi and Hirano, 1978).
3.2. Cell death
Cell death is a very important event in cells and just during the last years it has become clear that there 
are many different mechanisms with different morphological features involving various biochemical 
pathways. A prominent way of cell death is apoptosis, which is willingly induced by the cell by 
activating a special set of proteolytic enzymes (see below). Other possible mechanisms are necrosis, 
autophagic cell death, mitotic catastrophe and parthanatos, just to name a few. Since there is no 
common classification of the different pathways, mixing the different terms is an easy occurring 
mistake. Therefore a recommendation on the nomenclature of cell death is available, which aims to 
find a consensus on all the different mechanisms and terms used (Galluzzi et al., 2011).
Since only necrosis, apoptosis and parthanatos are of greater importance for this topic, only these three 
mechanisms are further described. 
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3.2.1.Necrosis
Necrosis is a form of programmed cell death, but it is usually not willingly induced by the cell, since 
its induction usually depends on extrinsic factors. This mechanism can be initiated under conditions 
like lack of blood supply, trauma or as a response to acute insult. Unlike in apoptosis, during necrosis 
cell content is released, triggering an inflammatory immune response, which results in direct damage 
to the surrounding tissue (Alberts et al., 2007). 
Typical morphological features occurring during necrosis are cell swelling and rupture of the cell 
membrane, whereas different from apoptosis, compaction of chromatin is not seen (Andrabi et al., 
2008) (see Figure 3). 
Figure 3 hematoxylin stainings; a shows healthy cerebellum-structure in which the cells are well-shaped and not 
showing any signs of damage (100x magnification); b shows necrotic tissue in which the cells are damaged and 
destroyed (100x magnification)
3.2.2.Apoptosis
Apoptosis is probably the most prominent and the best studied mechanism of programmed cell death 
occurring in an organism. Apoptosis plays a central role during development, but also in adult 
organisms, in which the process is induced in a strict regulated manner, keeping cell division and cell 
death in exact balance. Characteristic features that can be detected during apoptosis are cell shrinking, 
cell condensation, collapse of the cytoskeleton, a disassembling of the nuclear envelope, as well as 
chromatin condensation and DNA fragmentation (Alberts et al. 2007).
Galluzzi et al. described that until now four different modes of apoptosis can be identified. These are: 
1) caspase-dependent intrinsic apoptosis, 2) caspase-independent intrinsic apoptosis, 3) extrinsic 
apoptosis induced by death receptors and 4) extrinsic apoptosis induced by dependence receptors. As 
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the names already indicate in these modes a distinction is made between the inducing factors 
(intrinsically or extrinsically) and a distinction in the involvement of caspases (Galluzzi et al., 2011). 
Generally, caspases are known as aspartate-specific cysteine proteases and as members of the 
interleukin-1?-converting enzyme family. Up to now, 14 different caspases have been identified and 
they all share common features, like being synthesized as procaspases or zymogens. After activation 
through proteolysis, which can result from autoactivation or due to cleavage by another caspase, they 
build up the active heterotetrameric structure (Fan et al., 2005) (Launay et al., 2005). Alhough 
caspases show homologies, they exhibit different functions and accordingly a division into three 
subtypes can be done. The first group of caspases consists of enzymes that are known as apoptosis 
activators. They are mainly active at the start of the apoptotic signaling cascade and (because they act 
as activators) of downstream caspases. The second group consists of caspases that act as executioners 
or effector caspases and are activated in a rather late phase of the apoptotic signaling pathway. The last 
group consists of caspases that are involved in inflammatory processes which are not directly linked to 
apoptotic cell death (Fan et al., 2005). 
Since in the context of PML extrinsically induced apoptosis by cytotoxic T-lymphocytes (CTL) and 
granzyme B is the mechanism that is studied, a short overview on this pathway is given. Cytotoxic T-
cells are capable of inducing apoptosis in two different ways. Either CTL activate the apoptotic 
signaling cascade due to the interaction of TNF superfamily ligands or Fas/CD95 with their receptors 
or they release granzymes, which attack the cell membrane of the target cell and consequently induce 
activation of the caspase cascade due to cleavage of specific proteins (Afonina et al., 2010; Cullen and 
Martin, 2008; Russell and Ley, 2002). Granzyme B is known to act in two ways (shown in Figure 4). 
Since granzyme B is a CTL/NK protease, it can cleave substrates and was found to preferentially 
cleave after aspartates. Due to this function granzyme B is able to cleave caspases, especially caspase-
3, and is therefore activating the caspase signaling cascade (Adrain et al., 2005; Afonina et al., 2010). 
The other possibility is, that granzyme B is initiating the mitochondrial/apoptosome pathway by 
cleaving Bid, which induces oligomerization of Bax and/or Bak, which consequently leads to pore 
formation in the mitochondrial membrane. Through those holes proteins, such as cytochrome c, can 
leave these organelles and can induce the formation of the apoptosome, which also results in caspase-
activation and cell death (Afonina et al., 2010). 
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Figure 4 Apoptotic pathways induced by granzyme B; two mechanisms are shown; first one is the direct 
cleavage of caspase-3 by granzyme B which leads to activation of the signaling cascade. In the second way 
granzyme B cleaves Bid, which forms truncated Bid (tBid), which accordingly leads to Bax/Bak pore formation 
in the mitochondrial membrane. Through those pores cytochrome c can be released and induces the formation of 
the apoptosome consisting of Apaf-1 and caspase-9 which then induces further activation of the caspase 
signaling cascade (Afonina et al., 2010)
It is not clear, whether extrinsically induced apoptosis by CTL due to granzyme B release is really 
inducing oligodendrocyte death in PML patients. Currently, there are two studies available that are 
describing the presence of lymphocytes in the CNS (Aksamit et al., 1990; Wuthrich et al., 2006). 
Wüthrich et al. performed a study in which autopsy tissue out of HIV+ and HIV-patients was 
investigated with special interest of lymphocyte location towards JC virus infected oligodendrocytes. 
It was found that there are positive correlations of CD8+ cytotoxic T-cell, which were shown to be the 
most prominent subtype of immune cells located in the CNS parenchyma, with the JC virus infected 
cells. Therefore they argue that this apposition indicates a possible role of CTLs in killing 
oligodendrocytes, however it is also mentioned in the paper that due to usage of autopsy tissue there 
are experimental limitations resulting. Accordingly, it was not possible to distinguish if those CTL 
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found in the CNS parenchyma and closely located to the JC virus positive cells are really recognizing 
JC virus specific proteins or if their recruitment results from other attractants (Wuthrich et al., 2006). 
A major drawback of this paper is that they did not show that CD8+ T cells in the neighborhood of 
infected cells actually contain cytotoxic granules (no granzyme B or perforin stainings), nor did they 
reveal any indication that these cytotoxic T cells are polarized and actually release cytotoxic granules. 
Therefore further studies are needed to really identify the specific involvement of cytotoxic T-
lymphocytes in PML. 
3.2.3. A new cell death mechanism; Parthanatos
Recently, it was found that there exists another deathly pathway besides the well known cell death 
mechanisms such as apoptosis, necrosis and autophagy. This pathway was termed parthanatos. 
Parthanatos definitely differs from the cell death mechanisms listed above and induces cell death in a 
caspase-independent manner (Andrabi et al., 2008). The name of the mechanism already includes one 
of the two most central molecules constituting to the executive function of this pathway. The 
molecule, which is referred to here, is poly (ADP-ribose) or shortly PAR. This molecule is formed as a 
side product during the poly-adenylation reaction catalyzed by the enzyme poly (ADP-ribose)-
polymerase-1 (PARP-1) (Smith, 2001). PARP-1 is usually activated as a response to DNA damage. If 
the enzyme is activated, NAD+ is used as substrate and ADP-ribose polymers are attached to either 
acceptor proteins (heteromodification) or are transferred on PARP-1 (automodification) (D'Amours et 
al., 1999; Virag and Szabo, 2002). The extent of the damage occurring on the DNA has an influence 
on how the enzyme functions, since under rather low stress conditions the damage is repaired, whereas
under high stress conditions with extensive DNA-damage like in stroke or traumatic brain injury cell 
death is induced (Virag and Szabo, 2002). Due to the overactivation of PARP-1, high amounts of PAR 
are formed and the molecule accumulates in the nucleus (Andrabi et al., 2006). Somehow, PAR 
manages to translocate to the cytosol, but how this is achieved is presently unknown. At this point,
PAR is highly enriched in the cytosol and this is thought to be the starting point of the cell death 
cascade involved in parthanatos (shown in Figure 5). Interestingly, PAR colocalizes with mitochondria 
and these organelles are already known to contain cell death effector molecules, such as cytochrome c 
and the apoptosis inducing factor (AIF) (Beal, 2005). AIF, when first identified, was thought to be 
involved in cell death (Susin et al., 1999), but later was found to be also important in energy-
generating processes (Pospisilik et al., 2007). In the context of parthanatos, AIF plays a central role 
(Yu et al., 2006). The point of AIF release is generally handled as the commitment point for cell death 
in parthanatos (Andrabi et al., 2006). The exact mechanism, how AIF is released from the 
mitochondria, is still not totally solved, but it was found that AIF was released in an uncleaved form, 
as a 62kDa protein (Wang et al., 2009). In the brain, AIF seems to be associated with the outer 
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mitochondrial membrane and not to be only present in the intermembrane space, where it is located to 
the inner membrane. It was suggested that the localization at the outer membrane would enable AIF to 
be released very quickly during parthanatos and the amount of the molecule at this site would be 
sufficient to induce cell death (Yu et al., 2009). Recently, it was described that PAR is binding to AIF 
which is located at the outer mitochondrial membrane and due to this interaction AIF is released
(Wang et al., 2011). Once free, AIF is present in the cytosol and is translocated to the nucleus where it 
is capable of inducing large-scale DNA fragmentation, chromation condensation and cell death 
(Krantic et al., 2007; Modjtahedi et al., 2006). Generally, it is said that this cell death mechanism is 
independent of caspases, however in the late phase of parthanatos caspases get activated, as well. But 
since AIF is the deadly inducing factor in this pathway and caspases are only being activated at the 
late phase, they are not exhibiting an executioner function (Yu et al., 2002; Yu et al., 2006). 
Figure 5 Signaling involved during induction of poly(-ADP-ribose) polymerase-1 (PARP-1) dependent cell 
death (Parthanatos): Due to DNA damage, overactivation of PARP-1 an extensive PAR formation is induced. 
PAR usually present in the nucleus, is translocated by an unknown mechanism to the cytosol, where if AIF-
binding is possible, AIF release out of the mitochondria and translocation to the nucleus is achieved. AIF in the 
nucleus leads to DNA fragmentation and cell death (Wang et al., 2011)
Parthanatos or parthanatos-related events have already been described for some diseases. For example, 
it has been shown, that an increased amount of poly-ADP-ribosylated nuclear proteins is present in 
Alzheimer’s disease (Love et al., 1999). In addition, there is data available that poly-ADP-ribose 
polymerase-1 plays a crucial role in Parkinson’s disease (Mandir et al., 1999; Outeiro et al., 2007). 
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The paper of Veto et al which suggests that demyelination resulting from oligodendrocyte death in 
pattern III lesions of multiple sclerosis might be induced by parthanatos, is interesting regarding this 
topic. In this article experiments were performed using a mouse model, in which primary 
demyelination was induced by treatment with cuprizone. Mice treated with PARP-1 inhibitors 
revealed decreased demyelination. The conclusion was made that a caspase-independent cell death 
involving translocation of AIF to the nucleus was coming into account. Furthermore, it was concluded 
that inhibition of PARP-1 reduced death of oligodendrocytes, since PAR accumulation is avoided and 
therefore parthanatos would not be initiated (Veto et al., 2010). 
3.2.4.Current view on cell death in progressive multifocal leukoencephalopathy
Despite that it is a central pathological feature resulting in massive damage in patients, until now there 
is little data available on how oligodendrocytes actually die in PML. There are two studies published 
which are dealing with the question of oligodendrocyte death. Interestingly, these two papers are 
claiming different, even controversial mechanisms leading to cell death. One paper favors apoptosis as 
the death inducing mechanism (Richardson-Burns et al., 2002) whereas in the other study it is argued 
that apoptosis is not the inducer of oligodendrocyte death since anti-apoptotic proteins are found in the 
infected oligodendrocytes (Pina-Oviedo et al., 2007). Since the main topic of this thesis is to deal with 
the mechanism of oligodendrocyte death, the present view in this field will be shortly reviewed.
The paper published by Richardson-Burns S.M. et al. in 2002 shows that oligodendrocytes are 
dying due to apoptosis. The study was performed on 8 specimen gained out of PML-patients, whereas 
6 of them were HIV-positive and 2 were non-HIV patients. The methods used were 
immunohistochemical stainings with markers for the JC virus and for activated caspase-3, TUNEL 
staining and in situ hybridization. The results of the study show that virus infected oligodendrocytes 
are dying due to apoptosis, since cells are found showing a double labeling for TUNEL-staining and 
the virus marker, an anti-SV40 large T-antigen antibody. Interestingly, it was not possible to see the 
typical morphological changes, like chromatin condensation, usually appearing in a cell during 
apoptosis in the JC virus infected oligodendrocytes, though they are said to undergo this form of cell 
death in this paper. The authors also claim to find virus infected oligodendrocytes being positive for 
activated caspase-3, though they were not able to perform a double staining for activated caspase-3 
together with JC virus. Further it is argued that the number of virus infected oligodendrocytes and the 
apoptotic cells found in the area of interest are approximately the same and that therefore the 
conclusion can be made that all apoptotic cells were JC virus positive since virus infection is inducing 
the mechanism of apoptosis (Richardson-Burns et al., 2002). 
On the other hand, Pina-Oviedo et al. are describing an anti-apoptotic mechanism for JC 
infected oligodendrocytes. They point out, that the JC virus is capable of prohibiting apoptosis, the 
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normally induced host defense mechanism against virus infected cells, by the newly induced 
expression of the anti-apoptotic protein survivin. This protein is known to be highly expressed during 
embryonic development, but in adults and fully differentiated cells, it cannot be detected anymore and 
is consequently thought to be silenced in those cells (Li and Altieri, 1999). Pina-Oviedo et al. used 20 
autopsy samples of PML patients and performed immunohistochemical stainings for the presence of 
survivin. Interestingly they found that the anti-apoptotic protein is present in the JC virus infected cells 
and also confirm this by performing a double labeling for the virus and survivin. In oligodendrocytes,
survivin is detected in the nucleus and in the bizarre shaped astrocytes the protein is mainly located to 
the cytoplasm. To further proof the effects of survivin cell culture studies were performed. In those 
studies results are gathered that expression of survivin differed greatly in JC virus infected cells 
compared to non-JC virus infected cells. These observations are also seen in the autopsy tissue. To 
proof that survivin is really prohibiting apoptosis, there were comparative studies performed, in which 
apoptosis has been induced in JC virus infected cells, containing survivin, and control cells, in which 
survivin is absent. The results indicated that apoptosis is induced to a much higher extent in control 
cells compared to JC virus positive cells, which are rather unlikely to die. Due to all of these findings 
the authors claim that the virus inducing PML is capable of reinducing the expression of survivin. 
They argue as well that this mechanism would be beneficial for the life cycle of JC virus, because with 
survivin having anti-apoptotic effects, oligodendrocyte death is being prohibited and therefore the 
virus is able to finish its life cycle and can consequently replicate in higher amounts (Pina-Oviedo et 
al., 2007). By showing this data the authors found a nice concept how the virus might act, but still the 
central question of how oligodendrocytes are really dying is not clearly resolved. 
Having all the interesting and still controversial information given in those two papers cited above, it 
is rather difficult to distinguish which mechanism is really coming into account and inducing this 
extent of damage in the patient’s brains suffering from PML. Therefore a critical approach seems to be 
central for further investigations which definitely need to be done. 
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4. Materials and Methods:
4.1 Study-samples
In this study formalin-fixed and paraffin-embedded human autopsy tissue of patients suffering from 
progressive multifocal leukoencephalopahty (PML) (n = 8) collected by Professor Jellinger, patients 
suffering from hepatitis simplex encephalitis (HSV) (n = 5) and of patients suffering cytomegalovirus 
encephalitis (CMV) (n = 7), were the basic study samples of this work. 
All of the PML-patients suffered from HIV-infection as a primary disease. The disease duration for 
PML varied widely in all of the cases and the regions where the samples were taken from were also 
widespread. Unfortunately there was no information available about the patient’s history in the HSV-
cases. For the CMV-cases some data, but not the complete patient’s history was available. For more 
detailed information see Table 1.
Sample-
number Disease Age
Male/ 
Female
Disease 
Duration 
(wk)
Sample Area
Cause of 
Death
12-93-2 PML (HIV) 45 Male 118
Lenticular 
nucleus
Pulmunary 
edema
47-93-3 PML (HIV) 42 Male 20 Pons Pneumonia
97-93-8 PML (HIV) 50 Male 20 Parietal lobe right
Pulmunary 
edema
103-93-8 PML (HIV) 39 Male 15 Parietal lobe left
Acute 
respiratory 
insufficiency
278-93-6 PML (HIV) 29 Male 19 Parietal lobe left Cachexia
291-93-5 PML (HIV) 49 Female 5 Parietal lobe right Pneumonia
358-93-6 PML (HIV) 39 Male 27 Parietal lobe left Pneumonia
359-93-7 PML (HIV) 34 Male <18 Pons Pneumonia
330-82-4 HSV 9 Female 1,5 -
Acute 
respiratory 
insufficiency
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67-83-2 HSV 40 Male 3,5 -
Necrotic 
hemorrhagic 
pneumonia
204-83-4 HSV 61 Female 1,5 Pneumonia
529-84-6 HSV 37 Male 2,3 - Pneumonia
237-91-5 HSV 76 Male 3,15 - Pneumonia
364-92-4
CMV 
(Toxoplasmosis)
40 Male -
acute 
cadiovascular 
failure
455-92-7 CMV 48 Male <5 -
Pneumonia, 
Sepsis
559-92-11
CMV (HIV, 
Toxoplasmosis)
33 Male 20 Cerebellum right Pneumonia
234-93-4
CMV (B-cell 
lymphoma)
28 Male 11 Pons Pneumonia, 
Sepsis
430-93-6 CMV 35 Male 15 - Pneumonia
62-94-9
CMV (B-cell 
lymphoma) 32 Male
>4 Medulla 
oblongata
Pneumonia, 
Sepsis
118-94-5 CMV (HIV) 55 Male 9
Hippocampus 
right
Pneumonia
Table 1 Samples of PML-, HSV- and SSPE-patients included in the study
4.2 General staining procedures
4.2.1 Deparaffination
Since paraffin-embedded sections were used as a basis for the study, deparaffination needed to be 
performed for all of the different labeling methods used and described below.
Deparaffination was done by incubating the slides 2 times in xylene for 15 minutes and accordingly 
rinsing them twice in 96% ethanol. Depending on the staining blocking of endogenous peroxidase 
activity was performed by leaving the sections in 0,02% H2O2-methanol for 30 minutes. This blocking 
step was only needed in immunohistochemical stainings using peroxidase activity as a detection 
method. In all other labeling methods, (especially for confocal microscopy), this incubation time was
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skipped. Next rehydration followed and was achieved by leaving the sections shortly in 96% ethanol, 
70% ethanol, 50% ethanol and in aqua dest. 
4.2.2 Mounting
To avoid air bubbles, drying out of the tissue and bleaching of the staining the right mounting medium 
needs to be chosen as a final step to conclude the whole labeling procedure. 
When the staining was developed using DAB for detection the mounting medium of choice was 
Eukitt®. To use this medium the sections needed to be dehydrated in an ascending alcohol series (1x 
50% ethanol, 1x 70% ethanol, 3x 96% ethanol and ether) and were mounted out of ether with cover 
slips.
In case of fast blue, fast red or double labelings Geltol was used as embedding medium. Sections were 
not dehydrated, but were covered out of water, since otherwise all the staining would have been
washed away. The preparation of geltol is listed below.
Geltol: 60g liquid Geltol 
24g Mowiol
mixed for 30 minutes up to 1h
+ 60ml aqua bidest.
incubation for 2h
+ 120ml Tris (0,2M pH = 8,5)
heated to 50°C while mixing the solution
when 50°C were reached still left for a 10 minute-incubation time
centrifugation at 5000G for 15 minutes
storage at -20°C
To finish the staining for confocal microscopy the sections were mounted with Gallate-Geltol. This 
medium was very similar to geltol. There was just 0,1M Gallate included in the medium (0,2g gallate 
in 10ml geltol), which needed to be mixed with geltol overnight before use.
4.3 Hämalaun-Eosin staining
4.3.1 Materials:
• Mayer’s Hematoxylin (Merck®)
Materials and Methods
24
• 0.5% HCl-alcohol
• Scott’s solution: 2g KHCO3
20g MgSO4 x 7H2O
1000ml H2O
• Eosin stock solution: 10g eosin
100ml aqua dest
• Eosin ready-to-use solution: 2,5ml stock solution 
250ml aqua dest.
12 drops glacial acidic acid
4.3.2 Method:
For HE staining the sections needed to be deparaffinized. Accordingly, the slides were incubated for 5
minutes in Mayer’s Hematoxylin, washed 3-4 times with H2O and differentiated 5 times in HCl-
alcohol. Next, washing two times with H2O was performed, followed by incubation of the sections for 
5 minutes in Scott’s solution and rinsing with water. Dyeing in eosin solution was done by a 3 minutes 
incubation time and to continue the method two times washing with water was performed. As a last 
step the slides were dehydrated using an ascending alcohol series and were mounted with cover slips 
using Eukitt® for embedding. 
In the HE-staining the nucleic acids are colored in blue due to hematoxylin and collagen fibers and 
elastic fibers are dyed in pink due to eosin labeling. 
4.4 Klüver Barrera – PAS
4.4.1 Materials:
• 0,1% luxol fast blue: 1g luxol fast blue
1000ml 96% alcohol
• 0,1% hydrous lithiumcarbonate solution
• 70% ethanol
• 0,8% perjodic acid
• Schiff’s reagent
• sulfit washing solution
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4.4.2 Method:
Klüver-Barrera staining was performed on deparaffinized sections, but rehydration was skipped. 
Slides were rinsed two times in 96% ethanol and were incubated in 0,1% luxol fast blue at 57°C 
overnight. After cooling the sections down to room temperature, they were rinsed in 96% ethanol, 
followed by washing with aqua dest. Then incubation in 0,1% hydrous lithiumcarbonate solution was 
performed for 5 minutes at room temperature. To continue, the staining was differentiated in 70% 
ethanol until the background staining was nearly gone and only the staining of the myelin sheath was 
visible. The PAS-reaction (perjodic acid Schiff stain) followed these few steps. The reaction was 
started with rinsing the slides with aqua dest, incubation for 10 minutes in 0,8% perjodic acid, washing 
with aqua dest. and incubation for 20 minutes in Schiff’s reagent. Next, the sections were put two 
times for two minutes into sulfit washing solution and then washed for 5-10 minutes with tap water. 
Finally, the sections were dehydrated using an ascending alcohol series and mounted with Eukitt®.
The intention of the Klüver-Barrera – PAS staining is to make the myelin sheaths visible in blue and 
the grey matter in pink/red. In case of the viral encephalitis diseases being investigated here and in any 
other demyelinating diseases the demyelinated lesions get visible with this labeling. 
4.5 Immunohistochemistry
In immunohistochemistry so called primary antibodies (listed in Table 2) were used to bind to specific 
targets, which can be visualized using different methods. In most of the stainings biotinylated 
secondary antibodies and avidin-peroxidase were used to detect the specific markers. If double 
staining for light microscopy was performed different detection methods were combined, such as the 
Alkaline Phosphatase (AP) system with the diazonium salt Fast Blue (FB) with diaminobenzidine 
(DAB) or 3-amino-9-ethylcarbazole (AEC).
In case of confocal double labeling targets of investigation were tagged with different fluorescence 
dyes (Cy2, Cy3 and Cy5) for visualization.
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4.6 Primary antibodies used in the study
Antibodies
Antibody 
type Target Preatreatment Dilution Source
CD3
Rabbit (poly 
AB) Immune Cells
steamer 60' 
citrate/EDTA 
9.0
1:2000 with 
CSA Neomarkers
CD8
Mouse 
(mAB)
Cytotoxic T-cells steamer 60' 
EDTA 9.0
1:250 DAKO
GrB
Mouse 
(mAB) Granzyme B
steamer 60' 
EDTA 9.0
1:50 or 
1:1000 + 
CSA
Neomarkers
SV40
Rabbit (poly 
AB)
JC-Virus T-
Antigen
steamer 60' 
citrate/EDTA 
9.0
1:200 C or 
1:500 E
Santa Cruz
SV40
Rabbit (poly 
AB)
JC-Virus T-
Antigen
steamer 60' 
citrate
1:20000 with 
CSA or 
1:5000
Aliquot Dr. 
Höftberger 
(6.9.2011)
SV40
Mouse 
(mAB)
JC-Virus T-
Antigen
steamer 60' 
citrate
1:100 Calbiochem
Pab2003
Mouse 
(mAB)
JC-Virus VP1
steamer 90' 
EDTA 9.0
1:2000
Aliquot 
Frisque 
(27.03.06)
CMV
Mouse 
(mAB)
early antigen of 
CMV
steamer 60' 
EDTA 9.0 1:5000 Chemicon
HSV
Rabbit (poly 
AB)
HSV type I and II
steamer 60' 
citrate
1:1000 DAKO
CM1
Rabbit (poly 
AB)
Caspase 3 steamer 60' 
citrate
1:50000 with 
CSA or 
1:3000
Idun
Caspase-6
Rabbit (poly 
AB) Caspase-6
steamer 60' 
citrate 1:500 Abcam
AIF
Rabbit (poly 
AB)
Apoptosis 
inducing factor
steamer 60' 
citrate
1:250 Chemicon
AIF
Sheep 
(polyAB)
Apoptosis 
inducing factor
steamer 60' 
citrate/EDTA 
9.0
1:1000
R&D 
systems
PAR
Mouse 
(mAB)
Poly (ADP-
ribose)
no 
pretreatment
1:250
Aliquot Dr. 
Gallyas 
(16.10.08)
CAII
Sheep 
(polyAB)
Carbonic 
Anhydrase II
steamer 60' 
EDTA 9.0
1:1000 Binding site
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CNPase
Mouse 
(mAB)
2',3'-
cyclicnucleotide-
3'-
phosphodiesterase
steamer 60' 
EDTA 9.0
1:2000
SMI 91, 
Sternberger 
(25.2.05)
GFAP
Mouse 
(mAB)
Glial fibrillary 
acidic protein
steamer 60' 
citrate
1:200 Neomarkers
GFAP
Rabbit (poly 
AB)
Glial fibrillary 
acidic protein
steamer 60' 
EDTA 9.0 1:3000 DAKO
Table 2 Primary antibodies used in the study
In the table the markers are listed according to the target they are binding to. The first antibodies (1-5) 
are specific for immune cells, the following markers detect infected cells (6-8). Accordingly,
antibodies specific for targets involved in cell death are listed (9-12) followed by cell-type specific 
markers. 
Immune cell markers:
CD3: CD3 is a co-molecule arranged around the t-cell receptor (TCR) and is characterized by the 
immunoreceptor tyrosin-based activation motif (ITAM) (Reth, 1989). Due to phosphorylation by 
cytoplasmic kinases (Iwashima et al., 1994) CD3 gets clustered and conformational changes are 
initiated. All this events are needed to induce TCR-signaling (Minguet et al., 2007). Since CD3 is
expressed on all T-cells, it is commonly used as a marker for those cells (Bo et al., 2003).
CD8: CD8 is a transmembrane glycoprotein and serves as a co-receptor for the TCR. There are two 
possibilities how CD8 can be made up. One possible structure is the disulfide-????????2-homodimer 
and the other possible structure is a disulfide-??????? ??-heterodimer. CD8 shows in both 
conformations an immunoglobulin-variable like structure and also the same properties in the N-
terminal extracellular domains (Leahy et al., 1992). CD8 is predominantly expressed on cytotoxic T-
lymphocytes (CTL) and only rarely found on natural killer cells (NK-cells). The main function of CD8
is to specifically interact with MHC class I molecules (Swain, 1983). 
Granzyme B: Granzyme B is one of the five serine proteases, so called granzymes, which is 
expressed in human (Chowdhury and Lieberman, 2008). The enzyme is released by CTL and NK-
cells, if those cells interact with virus infected cells. In the infected cells granzyme B can induce cell 
death using two different pathways, one is the classical apoptosis pathway inducing the programmed 
cell death by cleavage of pro-caspase-3 to activated caspase-3. The other way is the promotion of 
mitochondrial permeabilization and cytochrome c release due to cleavage of BH3 interacting domain 
death agonist (BID). Accordingly, DNA fragmentation is induced. (Adrain et al., 2005; MacDonald et 
al., 1999; Martinvalet et al., 2008).
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Virus markers:
SV40: The simian virus large T-antigen 40 is a multifunctional protein. It organizes the replication of 
the double-stranded viral genome and consequently the protein’s structure is optimized to exhibit this 
function (Meinke et al., 2011). The molecule shows three different functional domains, an N-terminal 
J-domain, an origin-binding domain (OBD) and a helicase domain (Pipas, 2009). The protein can 
assemble into single and double hexamers and according to its property it binds to specific DNA 
sequences on the origin of replication (ORI). 
PAb2003: The antibody called PAb2003 is binding to early proteins expressed by the JC-virus 
(Munoz-Marmol et al., 2004). 
HSV: The targets of the antibody are HSV-type I and type II. 
CMV: CMV-antibody labels the virus infected cells through binding to an immediate early non-
structural antigen (68-72kDa). 
Markers for targets involved in cell death: 
CM1: The so called CM1 antibody detects the enzyme caspase-3. Caspase-3 belongs to the family of 
cystein-aspartic acid proteases. Caspase-3 is usually present in the cytosol as an inactive form, namely 
pro-caspase-3 and only upon activation of initator caspases (-2, -8, -10), which are acting more 
upstream cleavage and initiation of caspase-3 executioner activity can be induced. The direct 
consequence of caspase-3 activation is programmed cell death (apoptosis) (Olsson and Zhivotovsky, 
2011).
Caspase-6: Caspase-6 is like Caspase-3 and -7 an executioner caspase. Like the other effector 
caspases the immature zymogen form of the caspase needs to be cleaved by initator caspases to 
convert into the active conformation (apo-caspase). Caspase-6 (like the other executioner enzymes) is 
known to lead to degradation of critical proteins, nuclear and cytoskeletal proteins and consequently to 
cell death (Vaidya and Hardy, 2011). But it was also found that caspase-6 is involved in non-apoptotic 
processes like axonal pruning during development (Nikolaev et al., 2009), B-cell activation and B-cell 
differentiation (Watanabe et al., 2008). 
AIF: Apoptosis inducing factor is a 67 kD flavin-adenine dinucleotide containing, NADPH-depending 
oxidoreductase (Miramar et al., 2001). It is residing in the intermembrane space of mitochondria and is 
cleaved upon apoptotic insult (Otera et al., 2005), gets released and translocates to the nucleus, where 
it induces large-scale DNA-fragmentation in a caspase-independent manner (Cande et al., 2002). 
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PAR: Poly(ADP-ribose) is a negatively charged molecule that is synthesized by poly(ADP-ribose)-
polymerase-1 out of nicotineamide adenine dinucleotide (NAD) (D'Amours et al., 1999). The 
molecule can selectively interact with target proteins that are involved in reactions such as DNA 
repair, DNA metabolism and can bind to PARP-1, it’s synthesizing molecule (Virag and Szabo, 2002). 
Additionally, PAR is thought to play a central role in the new cell death pathway parthanatos. 
Normally, PAR is remaining in the nucleus, just in parthanatos-inducing conditions it translocates and 
accumulates in the cytosol (Andrabi et al., 2006) (Andrabi et al., 2008). 
CNS-cell type specific markers:
CAII: Carbonic anhydrase II is one of the 16 isoforms of human metalloenzymes (Saada et al., 2011). 
Its function is to catalyze the hydration of CO2. This reaction is mediated by the transfer of a water 
proton bound to zinc(II) of CA and as a side reaction is also resulting in the generation of a zinc 
hydroxide species of the enzyme (Pastorekova et al., 2004). In the brain CAII is most dominantly
localized to oligodendrocytes and can therefore be used as a detection marker for those cells. CAII is 
further present in the myelin and choroid plexus epithelium (Kida et al., 2006).
CNPase: 2’,3’-cyclic nucleotide 3’-phosphodiesterase is specifically expressed in myelin and located 
to the cytoplasm of non-compact myelin. The enzyme catalyzes the phosphodiester hydrolysis reaction 
of 2’,3’-cyclic nucleotides to 2’-nucleotides (Brunner et al., 1989) (Kursula, 2008).
TPPP/p25: Tubulin polymerization promoting protein is a member of the tubulin binding-proteins. 
TPPP/p25 is located to tubulin/microtubules. It is implicated in the stabilization of the microtubule 
network and in microtubule assembly in vitro (Vincze et al., 2006). In the brain TPPP/p25 is found in 
myelinating oligodendrocytes and neurons, but not in astrocytes (Cahoy et al., 2008). Further,
TPPP/p25 is involved in oligogenesis, especially in the differentiation of oligodendrocytes (Lehotzky 
et al., 2010). 
GFAP: Glial fibrillary acidic protein is a brain-specific intermediate filament expressed by astrocytes 
and Schwann cells. Like all intermediate filaments GFAP is involved in the cell shaping. However, it 
is also thought to be involved in calcification and chondrocyte differentiation due to its expression in 
elastic cartilage and cartilaginous differentiating tumors (Kepes and Perentes, 1988) (Webster et al., 
1985).
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4.7 Secondary antibodies used in the study
Secondary antibody Target Dilution Source
sheep-bi-?-mouse IgG (H+L) 1:500 Jackson 
Immunoresearch
donkey-bi-?-mouse IgG (H+L) 1:1500 Jackson Immunoresearch
donkey-bi-?-rabbit IgG (H+L) 1:2000 Jackson Immunoresearch
donkey-bi-?-sheep/goat - 1:200 Amersham Bioscience
donkey-?-mouse AP IgG (H+L) 1:200 Jackson Immunoresearch
donkey-?-rabbit AP IgG (H+L) 1:200 Jackson Immunoresearch
Table 3 Secondary antibodies (biotinylated and coupled to AP) used for light microscopy
4.8 Secondary antibodies used for confocal fluorescence microscopy
Antibody Target Labeling Dilution Source
donkey-?-mouse IgG (H+L) Cy3 1:200 Jackson 
Immunoresearch
donkey-?-mouse IgG (H+L) DyLight 488 1:100 Jackson Immunoresearch
goat-?-mouse IgG1 Alexa Fluo 488 1:100 Molecular Probes
goat-?-mouse IgG 2a Alexa Fluo 546 1:100 Jackson Immunoresearch
goat-?-rabbit IgG (H+L) Cy2 1:100 Jackson Immunoresearch
goat-?-rabbit IgG (H+L) Cy3 1:100 Jackson Immunoresearch
goat-?-rabbit IgG (H+L) Alexa Fluo 488 1:200 Molecular Probes
donkey-?-rabbit IgG (H+L) Cy2 1:200 Jackson Immunoresearch
donkey-?-rabbit IgG (H+L) Cy5 1:200 Jackson Immunoresearch
donkey-?-rabbit IgG (H+L) DyLight488 1:100 Jackson Immunoresearch
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donkey-?-sheep IgG (H+L) Cy3 1:100 Jackson Immunoresearch
donkey-?-goat IgG (H+L) Cy5 1:100 Jackson Immunoresearch
Table 4 Secondary antibodies used for confocal laser fluorescence microscopy specific for the various species 
and coupled to different fluorescent dyes
4.9 ABC-System using peroxidase activity for detection
4.9.1 Materials:
• 0,02 % H2O2 – Merthanol: H2O2: 30% (Merck)
• EDTA (pH = 9 or pH = 8,5) (pretreatment-solution)
• Citrate-buffer (10mM) (pretreatment-solution)
• TBS (pH = 7,5) (wash buffer)
• PBS ready to use: PBS-stock (0,2M Phosphate buffer (Sörensen) diluted 1:4 with A.dest.
(wash buffer)
• 10% FCS/Dako: fetal calve serum (Cambrex®) 
DAKO® wash buffer (code S 3009) diluted 1:10
• primary antibodies and biotinylated secondary antibodies (see Table 2 and Table 3)
• avidin-HRP(Sigma-Aldrich®): 1:100 in 10%FCS/Dako
• biotinylated tyramine stock (CSA-stock): 6ml borate buffer (pH = 8,0) (Merck®)
15ml sulfo-NHS-LCS-biotin (Pierce, Illinois, 
USA)
4,5mg tyramin (Sigma-Aldrich®) 
? left for stirring overnight, filtered and 
stored in small aliquots at -20°C
• CSA used solution: 20µl CSA
20ml PBS
20µl H2O2
• avidin-HRP (1:200) in 10%FCS/Dako
• DAB: 1ml DAB (K3467 DAKO®) stock solution
50ml PBS
16,5 µl H2O2
• AEC: 1,15ml AEC (K3464 DAKO®) stock
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50ml cold sodium-acetate-buffer (0,05M pH = 5)
25µl H2O2
4.9.2 Method:
All investigations were performed on paraffin-embedded tissue that was cut into 3-5µm thick sections. 
To start immunohistochemical stainings the sections were first deparaffinized, the endogenous 
peroxidase activity was blocked and rehydration was performed, as described earlier.
For antigen retrieval the deparaffinized sections were pretreated in EDTA (pH = 9 or pH = 8,5) or 
Citrate-buffer in a common house hold steamer (MultiGourmet FS20; Braun, Kronberg/Taunus, 
Germany) for one hour or 90 minutes. Depending on the used antibody the appropriate pretreatment
solution and pretreatment-duration (60 minutes or 90 minutes) were chosen (see Table 2). After 
cooling down to room temperature the slides were washed 3-5 times with tris buffered saline (TBS) or 
phosphate buffered saline (PBS). Unspecific background signal was reduced by blocking with 10% 
FCS/Dako® for 20 minutes in a hybrid chamber at room temperature. The next step was to dilute the 
primary antibody for the target of interest in the right proportion (Table 2) in 10% FCS/Dako®. This 
application was performed overnight at 4°C. The slides were rinsed in TBS or PBS for 3-5 times after 
this incubation time and subsequently a biotinylated secondary antibody that was able to bind the 
primary antibody was applied, diluted in 10% FCS/Dako® (see Table 3) and left for incubation in a 
humid chamber on a slow shaker for one hour at room temperature. After washing the sections with 
TBS or PBS for 3-5 times, a one hour incubation period with avidin horse radish peroxidase (HRP) 
complex (1:100) was performed, followed by a washing step with buffer (TBS or PBS). 
If necessary the labeling was amplified using biotinylated tyramine (King et al., 1997) (Bien et al., 
2002), followed by washing and incubation with avidin-HRP (1:200) for 30 minutes at room 
temperature on a slow shaker.
To visualize peroxidase activity either diaminobenzidine (DAB) or 3-amino-9-ethyl-carbazole (AEC) 
could be applied. To stop the enzyme reaction the sections were rinsed with deionized H2O for several 
times. 
Counterstaining was performed with Mayer’s hematoxylin (10-20 seconds), followed by washing with 
H2O, shortly rinsing in HCl-alcohol, washing with H2O, blueing in Scott’s solution and dehydration in 
an ascending alcohol series (1x 50%, 1x 70%, 3x 96% and 1x ether). Finally, sections were mounted 
and were left for drying at room temperature for some hours before further examinations.
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4.10 ABC-system using alkaline phosphatase activity for detection
4.10.1 Materials:
• avidin-AP: 1:100; Sigma-Aldrich®
• fast blue 50ml solution: 6,25mg naphtol-AS-MX-phosphate
+ 312,5 µl DMF
+ 50ml warm Tris/HCl buffer (0,1M pH = 8,5)
12,5mg fast blue BB salt mixed
+ 312,5µl 2N HCl
+ 312,5µl 4% NaNO2
???????????????????-solution
+ 77µl 1M Levamizole 
incubation for 2 minutes at 37°C
filtration
• All other materials (like wash buffer, pretreatment solution) were identical to those listed in
the materials-part for ABC-system using peroxidase activity for detection.
4.10.2 Method:
Instead of using peroxidase activity as a detection method alkaline phosphatase (AP) activity can also 
be used to visualize the interesting targets. Generally, there was little difference between these two 
methods. The sections were deparaffinized, pretreated for antigen retrieval and primary antibodies as 
well as secondary antibodies were applied as mentioned above. The difference was that avidin alkaline 
phosphatase (AP) (1:100) was applied instead of avidin-HRP for one hour at room temperature on the 
slow shaker. 
To visualize the labeling fast blue salt was used. Since development of the fast blue signal could take 
more time than DAB or AEC development, sections could be incubated in the fast blue solution up to 
45 minutes at 37°C. As in the other staining methods the labeling reaction was stopped by washing the 
samples with water. 
Counterstaining with Mayer’s hematoxylin can be performed, but in case of double labeling using 
SV40 as one of the primary antibodies, counterstaining was not part of the staining protocol due to a 
weak SV40-labeling and a possible confusion of the two (blue) signals.
Materials and Methods
34
Covering was done using Geltol as a mounting medium. To keep the sections free form air bubbles 
they were left in the fridge for drying overnight. 
4.11 Double Labeling for Light Microscopy
4.11.1 Materials:
The materials for double stainings for light microscopy are all the same as in the single labeling for 
light microscopy (see in detail in 4.9.1and 4.10.1). 
4.11.2 Method:
Light microscopical double staining was performed as described earlier for ABC-system. Just some 
small changes were made. Pretreatment was chosen according to signal intensity and antibody 
efficiency in order to get the right targeting for both of the primary antibodies used. Then the optimal 
pretreatment was chosen, which was mainly depending on the antibody giving the weaker signal. 
Different primary antibodies of different species were simultaneously applied on the deparaffinized 
sections overnight at 4°C. Dilution of the antibody changed only for the primary antibody that was 
directly conjugated to a detection system to a less diluted concentration. After washing with TBS or 
PBS a second incubation with the primary antibody solution was performed for one hour at room 
temperature. This step was supposed to intensify the labeling. This was again followed by washing 
with buffer (TBS or PBS). The different secondary antibodies were applied simultaneously at room 
temperature. There was always one secondary antibody used directly conjugated to a certain detection 
method (like f. ex. ?-mouse-AP) and one biotinylated secondary antibody. Depending on the use of 
secondary antibodies avidin-HRP or avidin-AP diluted 1:100 in 10%FCS/Dako was applied on the 
sections for one hour at room temperature.
To finish the staining alkaline phosphatase activity could be visualized with the diazonium salt fast 
blue or with fast red and peroxidase activity could be visualized either with DAB or AEC (described 
earlier). These reactions were performed after each other and depending on the target of interest and 
their signal intensity the right order for developing was chosen. To stop the detection reactions the 
slides were rinsed with H2O and mounted with cover slips out of water with Geltol as the embedding 
medium.
All incubations at room temperature were performed on a slow shaker and in a humid chamber, just as 
incubation overnight at 4°C was done in a humid chamber, to keep the sections from drying out. 
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If there were double stainings performed using two primary antibodies coming from the same species 
the protocol was modified once more. In this case the antibodies were not applied simultaneously, but 
were incubated on the sections after each other. First antigen retrieval was performed as usual, 
followed by overnight incubation with the first primary antibody. Then application of the secondary 
antibody solution and the avidin solution were performed. According to the staining method used the 
proper avidin either coupled to horse radish peroxidase or alkaline phosphatase was chosen. 
Visualization of the first antibody was achieved mostly with diazonium salt fast blue. After stopping 
this labeling reaction the slides were once again kept in the household steamer (for 15-30 minutes) in 
the best suiting buffer (citrate or EDTA). This incubation was not necessarily performed to obtain a 
better signal of the second antibody, but was done to denature all the unbound staining components 
still remaining from the first reaction and therefore avoid cross reactions and reduce the background 
signal in the second staining reaction. All further steps were performed as mentioned above 
(incubation with primary antibody overnight, application of secondary antibody solution and avidin-
solution each for one hour). In some cases MACH4 system was used (after overnight incubation with 
the primary antibody). The advantage of this system is that there is no need for using another 
biotinylated secondary antibody and therefore chances of cross reaction and background signal are 
reduced. To achieve a proper staining with this system the sections were incubated for 15 minutes first 
with MACH4-mouse probe, followed by washing and incubation with HRP-polymer (MACH4) for 15 
minutes. If a primary antibody taken out of rabbit was used only application of HRP-polymer 
(MACH4) for 30 minutes was performed. As a last step the labeling was visualized by using 3,3’ 
diaminobenzidine tetrahydrochloride hydrate (DAB). Sometimes ammoniumnickelsulfate (1%) (1ml 
to 50ml DAB) and cobalt (II)-chloride (1%) (0,6ml to 50ml DAB) were added to the DAB solution to 
intensify the staining and enhance the contrast of the labeling. 
4.12 Confocal Laser Fluorescence Microscopy
4.12.1 Materials:
• Dako-Diluent (code S2022)
• primary antibodies (see Table 2)
• 10% FCS/Dako®: FCS (Cambrex®)
Dako®-wash buffer (S3006) diluted 1:10 with A.dest.
• secondary antibodies (biotinylated and conjugated to cyanine dyes) (see Table 3 and Table 4)
• streptavidin conjugated to fluorescent dye (Jackson ImmnuoResearch) 1:75
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• Dapi (Sigma-Aldrich®) 1:10000 in PBS
• TBS (pH = 7,5) or PBS as a wash buffer
4.12.2 Method:
Except for small variations fluorescence immunohistochemistry was performed very similar to double 
labeling for light microscopy with small variations. In case of a double staining for confocal 
microscopy blocking of the deparaffinized sections was performed with Dako-Diluent. Both primary 
antibodies of the two different species were used more concentrated than in single labeling IHC and
were diluted in Dako-Diluent. Application was performed simultaneously at 4°C overnight. The slides 
were washed with TBS or PBS and incubation with primary antibody solution was repeated for one 
hour at room temperature. After washing with buffer (TBS or PBS), application of secondary antibody 
solution (see Table 4 for dilutions), containing one biotinylated secondary antibody and one directly 
fluorescence conjugated secondary antibody diluted in 10% FCS/Dako®, followed for one hour at 
room temperature on a slow shaker. The staining was continued by incubation with streptavidin 
conjugated to a fluorescence dye for one hour at room temperature, washing and counterstaining with 
4’,6’-diamidino-2-phenylindole (Dapi) for 5 minutes at room temperature. Mounting of the slides with 
cover slips was done using gallate-geltol as a mounting medium. 
In case of a triple labeling the three different antibodies of different species were applied 
simultaneously, as well as the secondary antibodies were applied together (as mentioned above). All 
other steps were performed identically. 
During incubation times the sections were always kept in a light proof humid chamber to avoid drying 
of the samples and the dyes from bleaching. 
Fluorescent preparations were examined using a confocal laser scan microscope (Leica SP5; 
Mannheim, Germany).
4.13 Quantitative analysis
In order to gain some quantitative information about the investigated sections, manual counting on the 
microscope was performed. Therefore an ocular grid was used. Most of the countings were done using 
the 20 times magnification objective to make sure that the cells showing the right properties were 
counted. With this magnification the grid has a length of 0,48mm and a total volume of 0,2304mm2. 
Along with these grid values and the counted cell values the amount of cells present in 1mm2 was 
calculated. If the area, in which the counting was performed, did not contain any cells showing the 
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properties under investigation, the area was enlarged and consequently other grid values for counting 
were used. 
For statistical analysis IBM SPSS 18 was used. Since our data showed an uneven distribution and due 
to the low case number, we only performed nonparametric tests. In the comparison of the data a pair 
wise calculation of significant differences between two diseases was performed. This calculation was 
achieved using the Mann-Whitney-U-test. Generally p-values below 0,05 were considered to be 
significant. 
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5. Results
5.1 Basic pathological features in viral encephalitis
In this study paraffin-embedded PML samples of 8 different HIV+ patients were used for the
experiments. Firstly, histochemical stainings with luxol fast blue for myelin sheaths for visualization 
and localization of the demyelinating lesions in the white matter of our PML samples were performed. 
The next step was the immunohistochemical labeling for the presence of virus infected cells with the 
SV40 antibody (performed by Dr. Höftberger on the AKH in Vienna), detecting the T-antigen of JC-
virus. In this SV40 staining it could be observed that the infected oligodendrocytes were present on the 
edge of the lesions, whereas in the lesion center no infected oligodendrocytes could be detected. The 
fact that the infected cells were primarily oligodendrocytes was verified using a double labeling for 
SV40 T-antigen and CAII as a marker for oligodendrocytes. Bizarre shaped, virus containing 
astrocytes were found in the middle of the demyelinating lesion. These bizarre cells were astrocytes as 
seen by double staining for the JC-virus and GFAP an astrocyte marker (shown in Figure 6).
On the basis of the SV40 labeling, information on lesion size and amount of cells that are 
containing JC-virus was gained. Most of the virus infected oligodendrocytes were found in sections 
with many small lesions that were in close vicinity with each other and sometimes also connected to 
each other due to lesion spreading. In big lesions virus infected oligodendrocytes were found
predominantly on the border whereas virus containing astrocytes were mainly detected in the lesion 
center. Virus expressing oligodendrocytes were usually characterized by the presence of a round 
swollen nucleus that was much bigger in size than the nucleus in non-infected oligodendrocytes.
Generally, it was found that also the cytoplasm of these virus infected oligodendrocytes were enlarged
compared to their usual appearance. This typical property could also be used for identification of 
infected oligodendrocytes in other stainings. Infected astrocytes could be identified due to their 
strikingly enlarged nucleus and swollen cytoplasm, which is very different from the usual astrocyte 
appearance. 
An interesting additional feature that could be detected in the virus staining was that some of the cells 
labeled with the JC-antibody appeared to be degenerating. The cell body of these cells was blebbing, 
whereas their nucleus was shrinking and the chromatin was seen to become condensed. Astrocytes 
were seen to be enlarged and their cytoplasm was seen to be totally full with JC-virus, but astrocytes 
were not seen to degenerate. The results of the JC-virus stainings were fundamental for all our 
following experiments, since we gained knowledge about the special properties of each sample used.
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Figure 6 Labeling of SV40 infected cells for confocal laser microscopy (630x magnification used in all pictures): 
a shows a virus infected oligodendrocyte, whereas the virus marker was visualized with DyLight549 in red and 
CAII the oligodendrocytemarker was visualized with Cy5 seen here in blue; b shows a virus infected astrocyte 
(SV40 is seen in red (DyLight549) and GFAP is labeled in green (DyLight488)); c virus infected 
oligodendrocyte (double labeled with DyLight549 (SV40) and Cy5 (CAII) and an astrocyte that is not virus 
infected; d double labeled astrocytes for GFAP (DyLight488) and SV40 (DyLight549)
Typical properties seen in CMV encephalitis were that the infected cells were mainly present around 
ventricles or areas to which CSF had access. The infected cells which were mainly neurons and 
astrocytes appeared highly enlarged and showed viral inclusions in the nucleus. The typical “owl eye” 
shape was seen in many of the infected cells. This special feature was used in later stainings to identify 
the infected cells. Further microglia nodules were observed as well as necrotic lesion appeared in the
in the brain parenchyma, resulting in cell loss. 
In HSV encephalitis as well as in the CMV encephalitis necrotic lesions were observed. Additionally, 
to the necrotic lesions also hemorrhagic properties were observed in the lesions of the HSV 
encephalitis patients. HSV infected cells were not showing any special properties which would have 
facilitated identification. Therefore stainings for different cell type markers were performed in order to 
identify the underlying cell type. The results showed that mainly neurons, astrocytes and 
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oligodendrocytes were infected with HSV. The virus was present in the nucleus as well as in the 
cytoplasm. 
5.2 Inflammation in viral encephalitis
To gain more information about the role of inflammation in this viral encephalitis disease staining for 
CD3 (a general T-cell marker), CD8 (a marker for cytotoxic T-lymphocytes) and labeling for 
granzyme B (GrB), a protease released by cytotoxic T-lymphocytes (CTL) as defense mechanism, was 
performed. 
Figure 7 Immune cells invading the brain parenchyma; a-c DAB stainings for CD3; a CD3 cells in PML tissue 
(40x magnification); b CD3 in CMV encephalitis is already showing appositions with the infected cells (100x 
magnification); c CD3 in HSV encephalitis 1(00x magnification); d-f DAB staining for CD8; d CD8 cells in 
PML (40x magnification); e CD8 in CMV encephalitis (100x magnification); f CD8 in HSV encephalitis (100x 
magnification); g-i DAB staining for GrB; g GrB positive cells in PML (250x magnification); h GrB cells being 
in apposition with CMV infected cells in CMV encephalitis (250x magnification); i GrB positive cells in HSV 
encephalitis (250x magnification)
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To compare the results of our investigations on the PML-samples and check for similarities in other 
viral encephalitis diseases, the experiments described above for PML were performed in the same way 
on samples taken from patients suffering from herpes simplex encephalitis (HSV) and 
cytomegalovirus encephalitis (CMV) (see Figure 7). After immune cell quantification (see Table 5) 
statistical comparison of the number of cells stained for CD3, CD8 and GrB in the three different 
diseases was performed.
PML-cases CD3/mm2 CD8/mm2 % CD8 of 
CD3
GrB/mm2 % of 
CD3
12-93-2 55 40 72 0 0
47-93-3 96 79 82 22 23
97-93-8 53 47 88 11 21
103-93-8 49 29 59 10 20
278-93-6 228 180 79 66 29
291-93-5 42 23 53 8 18
358-93-6 89 59 66 26 29
359-93-7A2 42 15 36 2 6
MEAN 82 59 67 18 18
SD 62,35 53,14 17,07 21,29 10,32
HSV-cases CD3/mm2 CD8/mm2 % CD8 of 
CD3
GrB/mm2 % of 
CD3
237-91-5 104 112 109 6 6
67-83-2 154 110 72 96 63
529-84-6 99 54 54 4 4
204-83-4 140 38 27 3 2
330-82-4 56 16 28 12 22
MEAN 110 66 58 24 19
SD 39 43 34 40 25
CMV-cases CD3/mm2 CD8/mm2
% CD8 of 
CD3
GrB/mm2
% of 
CD3
62-94-9 46 44 96 4 9
455-92-4 23 23 100 10 42
118-94-2 72 69 96 30 42
364-92-4 48 40 83 6 13
430-93-6 3 3 88 1 41
559-92-11 40 38 95 19 49
234-93-4 34 24 70 7 21
MEAN 38 34 90 11 31
SD 22 21 10 10 16
Table 5 Quantification data from PML, HSV encephalitis and CMV encephalitis
First analysis of the amount of CD3+ T-lymphocytes present in the brain parenchyma in the 3 forms of 
encephalitis was performed. Comparison of the PML cases with the HSV encephalitis cases showed 
an insignificant difference (p = 0,057). When PML was compared with CMV encephalitis, the result 
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showed significant statistical difference (p = 0,028). Another significant difference was seen in the 
comparison of HSV encephalitis with CMV encephalitis (p = 0,007). Next, the data for the CD8+ T-
lymphocytes, which was set in relation to the amount of CD3+ cells, was compared between the three 
diseases. When checking for significant differences between PML and the other encephalitides we 
found again no difference with HSV (p = 0,380), but a difference with CMV encephalitis (p = 0,011). 
The results for the comparison of HSV encephalitis with CMV encephalitis revealed an insignificant 
result (p = 0,122). As a last step we also compared the data for the presence of GrB in relation to the 
amount of CD3+ T-cells. Interestingly the detailed comparison of the three diseases indicated no 
significant difference between PML and HSV and PML and CMV as well as between HSV and CMV 
found (PML vs HSV: p = 0,661; PML vs CMV: p = 0,132; HSV vs. CMV: p = 0,223) (see Figure 8).
Figure 8 a amount of CD3/mm2, CD8/mm2 and GrB/mm2 arranged in groups for each disease, the clamps 
indicate the significant differences obtained during comparison; b amount of CD8 (%) and GrB (%) set in 
relation to the amount of CD3 positive cells present in the brain parenchyma
In all three encephalitides it could be shown that viral infection resulted in recruitment of immune 
cells into the brain parenchyma, especially to sites of demyelinating lesions. In a double staining it
could be visualized that CD8+ cytotoxic T-cells and JC-virus containing cells were present in the same 
area, further it was observed in another staining that 29% of those CD8+cytotoxic T-cells were 
containing GrB in PML. Double stainings using GrB and SV40 as markers verified that GrB+ cells 
could be found in the same areas as the infected cells. Generally, these results are indicative for an 
involvement of the immune system in initiation of cell death in virus infected cells. However, since 
close contact of CTLs with their targets is absolutely needed, the appositions (single or multiple) of 
GrB containing cells with JC-infected cells were specifically analyzed. This analysis revealed that 
close apposition of SV40 positive cells with GrB containing cells was absent in the brain parenchyma 
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of PML-patients. GrB positive cells were sometimes relatively close to JC-virus containing cells, 
however there has not been seen a direct contact of these cells. Quantification of the numbers of 
infected cells with single or multiple appositions of GrB+ cells in PML patients in comparison with 
HSV encephalitis and CMV encephalitis confirmed that appositions in PML were very rare. The 
comparison of PML with HSV encephalitis and CMV encephalitis revealed that the latter diseases had 
more appositions (see Figure 10). 
Figure 9 Double labelings for GrB (labeled with DAB in brown) and the different virus markers; a labeling for
SV40 with fast blue and GrB, showing that those cells are located in the same area, but no apposition was 
detectable (400x magnification); b multiple appostions of GrB positive cells towards the CMV infected cell 
(labeled with fast red), polarization of GrB towards the CMV positive cell can be seen and is indicated by the 
arrow head (400x magnification); c labeling of HSV infected cell (with fast red) and GrB, wheras the 
polarization of the cytotoxic granule is indicated by the arrow head (400x magnification)
The biggest difference was seen when comparing PML with CMV encephalitis. In this case statistical 
significance was detected (p=0,014), unlike the comparison of PML and HSV encephalitis which did 
not show significance (p=0,879). For HSV encephalitis and CMV encephalitis another insignificant 
result was obtained (p = 0,122) (shown in Figure 10). Moreover, unlike in PML, in CMV encephalitis 
it was even possible to detect multiple appositions, which means that multiple GrB+ cells are in contact 
with one single CMV positive cell. In the comparison of the data for multiple appositions between the 
three diseases a statistically significant result was seen between PML and CMV encephalitis 
(p=0,008), but not for PML with HSV encephalitis (p = 0,642) and CMV with HSV (p = 0,110) 
(shown in Figure 10). ). Another step in cytotoxic killing of target cells by cytotoxic T cells is 
polarization of the cytoplasm and directing the GrB granules towards the target cell. Such GrB 
polarization was described in in vitro cytotoxicity and was seen to highly augment the cytotoxic 
capacity of those granules (Wagner et al., 1993). In addition to the above-mentioned quantitative 
findings, we could observe such polarisations of GrB towards the virus-infected cell in CMV and HSV 
encephalitis but not in PML encephalitis (Figure 9).
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Figure 10 Single appositions (%) and multiple appositions (%) found in the three different viral encephalitides; 
clamps indicate the statistically significant differences between the different diseases
It has been shown in the past that infiltrating lymphocytes in brain of acute disseminated 
encephalomyelitis are eliminated by apoptosis (Bauer et al., 1999). During the examination of 
cytotoxic T cells in the brain presence of GrB+ cells with clearly condensed nuclei indicative for 
apoptosis was noticed (Figure 11). Quantitative analysis of such apoptotic GrB+ cells surprisingly 
showed that in PML these numbers were as high as 25%, whereas in HSV and CMV encephalitides 
these numbers were respectively lower and accounting for 4,8% and 4,8% (shown in Figure 12). 
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Figure 11 ABC staining for GrB; a normal appearing GrB carrying CTL (400x magnification); b apoptotic GrB 
containing CTL showing a condensed nucleus (400x magnification)
Figure 12 Amount of apoptotic GrB cells counted in the brain parenchyma of the different viral encephalitides; 
clamps indicate the statistical differences calculated for the different diseases; it can be seen that there were 
much more apoptotic GrB positive cells found in PML compared to HSV encephalitis and CMV encephalitis and 
that statistical difference was obtained in the comparison of PML to the other two diseases
In order to gain more information about the underlying mechanisms in the different viral encephalitis 
diseases the influence of executive caspases, which can be activated due to immune response and 
release of GrB, was under investigation investigated next.
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5.3 The role of caspases
Since caspases, primarily caspase-3, can be activated by granzyme B during the defense mechanism 
and because of their role as the key enzymes in apoptosis, they might exhibit a central function in the 
course of oligodendrocyte cell death in PML. Accordingly, labeling for activated caspase-3 and 
caspase-6, two of the main executioner caspases in apoptosis, were performed. In apoptototic cells,
caspase-3 is found in the cytoplasm (Bradl et al., 1999) (Bien et al., 2002) (Bauer et al., 2007). 
Inactive caspase-6 is present in mitochondria and thus shows a granular staining. During apoptosis 
caspase-6 diffuses from the mitochondria and can be found as a diffuse cytoplasmatic staining. The
results of these stainings showed that caspase-3 and caspase-6 were expressed in their inactive 
conformation, but were sometimes present in an upregulated manner in the virus infected cells in our 
PML-samples. None of the JC virus infected oligodendrocytes contained activated caspase-3 or 
caspase-6 (see Figure 13). Still, we observed that in our samples (mainly on the edge of lesions) some 
cells showed a typical apoptotic nucleus. This led to the conclusion that initiation of cell death 
resulting in tissue damage and presence of cells with condensed nuclei needs to be induced in another 
way than T-lymphocyte activation, GrB release and caspase-activation in PML. 
To compare the observed findings in the PML-cases with the HSV encephalitis and CMV encephalitis 
cases we also performed the stainings for caspase-3 and caspase-6 expression in those samples. The
results of the caspase labelings in the other two encephalitides revealed that their expression was up 
regulated like in PML. The search for activated caspase-3 and activated caspase-6 in HSV and CMV 
was successfully concluded since cells containing the activated enzymes could be found. To confirm 
that the activated caspases were present in virus-infected cells double stainings for activated caspase-3
and the particular virus marker were performed. In the CMV encephalitis we could nicely visualize a 
colocalization of the of the virus marker with caspase-3 or cytoplasmatic caspase-6. This was also seen 
in the HSV cases albeit in less high numbers. Furthermore, in both the HSV encephalitis and in the 
CMV encephalitis we could show that these caspase-3 or caspase-6 positive cells contained a 
condensed nuclei typical for apoptosis (see Figure 13). 
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Figure 13 Single labelings for caspase-3 (first row) and caspse-6 (second row) and double labeling for virus 
markers with caspase-3 (third row); a shows inactive caspase-3 in the PML-sample (indicated with an arrow) 
(400x magnification); b activated caspase-3 (marked with an arrow) that is very darkly stained and widely 
distributed in the cytoplasm can be seen (400x magnification); c HSV encephalitis sample showing an astrocyte 
positive for activated caspase-3 (400x magnification); d activated caspase-3 in HSV encephalitis whereas this
cell is already showing a condensed, apoptotic nucleus (marked with an arrow) (400x magnification); e staining 
for caspase-6 which is present in an upregulated manner , but though inactive and still granular (cells containing 
inactivated caspase-6 are marked with an arrow) (400x magnification); f caspase-6 present in its inactive 
conformation (granular staining) as well as the active conformation (distributed in the cytosol), cells containing 
caspase-6 in its active confirmation are pointed out by an arrow head (400x magnification); g inactive, but 
upregulated caspase-6 as well as clearly apoptotic cells (marked with an arrow) with their nucleus surrounded by 
activated caspase-6 can be seen (400x magnification); h double staining for SV40 (in blue) and caspase-3 (red) 
(marked with an arrow) whereas no double labeled cells were detected (400x magnification); i confocal laser 
microscopy stained for CMV (green (DyLight488)), caspase-3 (red (DyLight549)) and counterstained with 
DAPI (blue) showing cells being double labeled for the virus marker and caspase-3 (630x magnification); j-k 
double labeled cell with HSV and caspase-3, whereas the double labeled cell in picture k is indicated by an 
arrow (400x magnification)
Summarised, these findings suggest that an immune response resulting in the activation of caspases
induces apoptosis in HSV encephalitis and CMV encephalitis but that the situation for initiation of 
oligodendrocyte death is different in PML. 
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5.4 Cell death in PML goes via Parthanatos
According to the data shown above, the underlying cause for oligodendrocyte death in PML was very 
unlikely to be depending on the activation of CD8+ T-lymphocytes, release of GrB and initiation of 
apoptosis via activation of the caspase-cascade. Consequently, it was searched for another possible 
mechanism which was giving a better explanation for demyelination due to oligodendrocyte death in 
PML and which was also matching with the results described above. The in the introduction described 
form of cell death parthanatos was a likely candidate for the cell death in PML. Since poly-(ADP-
ribose) (PAR) and apoptosis inducing factor (AIF) were the key molecules in the parthanatos pathway, 
stainings for these two molecules were performed (Andrabi et al., 2008) (Wang et al., 2011). In the 
immunohistochemical labelings using the PML-samples we could nicely visualize that in the JC-virus 
infected oligodendrocytes PAR, was not only located in the nucleus, but was often also seen to 
translocate to the cytosol. Triple staining with SV40, PAR and CAII confirmed that mainly virus 
infected oligodendrocytes were containing PAR in the cytosol. Further we observed that AIF was not 
totally restricted to the mitochondria, as seen under normal conditions, but was also translocated out of 
the mitochondria to the nucleus where it was able to induce DNA-fragmentation. To get better 
evidence for these results double and triple stainings for confocal microscopy were performed, like 
SV40, AIF and PAR or AIF, PAR and CAII (shown in Figure 14). 
These labelings further proofed that in JC virus-containing oligodendrocytes PAR could be seen in the 
cytosol and AIF was colocalized with the virus staining in the nucleus. These observations support the 
theory that JC-virus-infection of oligodendrocytes initiates a process which leads to accumulation of 
PAR in the cytosol, translocation of AIF to the nucleus and as a last consequence to cell death. 
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Figure 14 Stainings for parthanatos markers (AIF and PAR) in PML; a PAR (stained with DAB) is usually seen 
to be present in the nucleus, but during cell death initiation is accumulating in the cytosol (250x magnification); 
b PAR is widely distributed in the cytosol (400x magnification); c AIF (labeled with DAB) is found in the 
mitochondria showing a granular staining, but during parthanatos is translocated to the nucleus (250x 
magnification); d AIF found in the nucleus (400x magnification); e-f confocal laser microscopy used to label the 
JC virus (in blue with Cy5) located in the nucleus, PAR (with DyLight488 in green) located in the cytosol of the 
virus infected cell and AIF (with DyLight549 in red) also found in the nucleus, overlay of the stainings in the 
nucleus result in a yellowish color (630x magnification); g confocal laser microscopy for visualization of SV40 
(with DyLight549 in red), PAR (with DyLight488 in green) and CAII (with Cy5 in blue) to verify that 
oligodendrocytes are the virus infected cells dying through parthanatos (630x magnification)
To further gain clear evidence that there were different mechanisms activated in the different viral 
encephalitis diseases single labelings for PAR and AIF were performed on the HSV encephalitis 
samples and CMV encephalitis samples. Surprisingly, it was found that PAR was present in the 
cytosol of some cells in HSV encephalitis. AIF, on the other hand could not be detected in the nucleus 
of any of the HSV encephalitis specimens. In the CMV encephalitis cases PAR could not be found in 
the cytosol. Also, AIF could not be seen to be translocated to the nucleus in the virus containing cells. 
To confirm this, we also performed triple stainings on those sections, using antibodies against the 
specific virus together with AIF and PAR. Again, we never found a translocation of PAR out of the 
nucleus into the cytosol and AIF out of the mitochondria into the nucleus in the virus infected cells 
(shown in Figure 15). 
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Figure 15 Confocal laser microscopy used to visualize parthanatos markers in CMV encephalitis and HSV 
encephalitis; a PAR (marked with DyLight488 in green) is mainly restricted to the nucleus and AIF (labeled with 
DyLight549 in red) is only seen as a granular staining only located in the mitochondria in CMV infected cells, 
DAPI staining is seen in blue and virus infected cells were identified due to their “owl eye” shape (630x 
magnification); b no indications for parthanatos can be found in HSV infected cells (labeled with Cy5 in blue), 
PAR (marked with DyLight488 in green) and AIF (stained with DyLight549 in red), since PAR was remaining 
in the nucleus and AIF was present in the mitochondria (630x magnification)
These findings strongly suggest that, unlike in PML, parthanatos is not the underlying cell death 
pathway in these two viral encephalitides
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6. Discussion
Demyelination and oligodendrocyte loss is a central feature occurring during the disease course of 
PML (Astrom et al., 1958). Though being this important, it has never been established which 
mechanism is actually leading to death of virus infected oligodendrocytes and therefore causing the 
demyelinating lesions in the white matter. Oligodendrocyte loss could be the result of various 
mechanisms. First, it might be a direct result from the virus infection. After infection the virus uses the 
oligodendrocytes system to create new virus particles. During this phase protein synthesis and energy 
metabolism are constantly at high levels. Since viral replication and maturation is tightly connected 
with the function of the endoplasmatic reticulum (ER) this organelle senses changes naturally 
occurring in infected cells. A high protein traffic through the ER as well as misfolded or unfolded 
protein release due to the viral infection, might initiate ER stress probably leading to apoptosis (He, 
2006). It might be that this overload finally leads to internal damage and death of the infected cells. 
Secondly, inflammation is abundant in the brain of PML-patients, but a link between the initiation of 
the immune response and death of oligodendrocytes has not described. Generally it is assumed that 
cytotoxic T cells kill virus infected cells. Cytotoxic T cells can kill target cells in a number of ways, 
whereas two groups of mechanisms are distinguished. First group is involving death receptors with 
appropriate ligand binding and the second pathway is a granule-dependent. Generally death receptor 
killing can be either induced by TNF-TNFR interaction or by interaction of Fas and its ligand FasL 
(CD95) leading to downstream signaling cascade activation. Granule dependent killing on the other 
hand involves release of perforin towards the target cell membrane in order to make holes in the 
membrane. This consequently enables GrB to enter the cell, where this protease is capable of initiating 
caspase-dependent apoptosis (Russell and Ley, 2002). To find out if the cytotoxic T cells are really 
involved in the pathogenesis of PML, presence of CD3+, CD8+ and GrB containing cells were 
analyzed first. The results showed that there are activated cytotoxic T-cells in the brain parenchyma. 
This finding was already described in a paper published by Wüthrich et al.. In this paper results are 
shown that CD8+ cytotoxic T-cells are located in the brain parenchyma and it is also claimed that 
appositions of CTLs and SV40 positive cells are found. The group interpreted these observations as an 
indication of cytotoxic T cell involvement in oligodendrocyte death (Wuthrich et al., 2006). However 
there were no experiments performed in this paper linking specific cytotoxic mechanisms directly to 
oligodendrocyte death, for instance it was not checked if cytotoxic granules were present in those 
CTLs being in apposition with virus-infected cells and therefore create the possibility that GrB release 
is responsible for oligodendrocyte apoptosis. Here the presence of GrB in the samples was counted 
and it was found that around 29% of CD8+ cells in the brain parenchyma carried GrB. In the double 
labeling it could also be shown that virus infected cells and GrB positive cells were present in the 
same area. However, although being located close to each other the search for appositions was not 
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successful. It was not possible to find any appositions of JC-virus containing cells with cells carrying 
cytotoxic granules. 
In the comparison of PML with HSV encephalitis and CMV encephalitis differences could be 
observed. Unlike the findings in PML, it was possible to find single appositions of GrB containing 
cells with the specific virus present in both HSV encephalitis as well as CMV encephalitis. However 
in CMV encephalitis a much higher frequency of single appositions could be detected and even a high 
frequency of multiple appositions of GrB+ cells to infected target cells was observed. This already 
manifested the idea that cytotoxic T-cells are involved in killing virus infected cells in CMV 
encephalitis. In HSV encephalitis on the other hand the situation was not this clear, but still there was 
a trend seen that activation of cytotoxic T-lymphocytes and GrB release plays a more crucial role than
in PML. 
At the present time it is unclear why in PML cytotoxic T cells do not seem to kill the infected cells by 
GrB release. A possible explanation could be that the infected cells are not detected by the cytotoxic T 
cells. In order to enable virus detection infected cells have to present viral proteins by MHC class I 
molecules (Adhya and Basu, 2010). Accordingly it could be estimated that JC-infected 
oligodendrocytes do not express these MHC class I molecules. Surprisingly, however, these infected 
cells revealed strong staining with HC10, an antibody recognizing the heavy part of the MHC class I 
molecule (Stam et al., 1990). However, viruses evolved various other mechanisms to escape the 
cytotoxic T-cell response. Possibilities to inhibit this response are to block the antigen processing and 
to interfere in the antigen transporter activity (Farrell and vis-Poynter, 1998). Consequences of these 
events are that no antigen is presented by the MHC class I, so no activation of cytotoxic T-cells is 
achieved and the virus can successfully escape cytotoxic T-cell killing. Other immune evasive 
strategies involve blocking of interferon-dependent signaling pathways (Smith et al., 1997) or changes 
in the chemokine or cytokine production in order to promote virus replication (Lalani et al., 2000)
(Tortorella et al., 2000). Such mechanisms have not been described in PML.
Due to all these results the idea was formed that there was a difference in the involvement of the 
cytotoxic T cells between the three different viral encephalitis diseases. Since it was observed that 
25% of GrB positive cells were apoptotic in PML the frequency of apoptotic GrB cells in the HSV 
encephalitis and CMV encephalitis was counted as well. The incidence rate for apoptotic GrB cells in 
these diseases was dramatically lower than in PML. In the HSV encephalitis as well as CMV 
encephalitis the same level of apoptotic GrB cells was observed. How apoptosis is induced in GrB 
carrying cells in PML is not known, but one could speculate that the JC virus evolved this strategy to 
escape cytotoxic T-cell killing. Inducing, apoptosis in GrB cells would be beneficial for the JC virus 
since those cells cannot exhibit their original function of GrB release into the target cell. Accordingly,
the virus can further replicate and multiply. Of course these results were further enforcing the idea of 
different underlying mechanisms in the different diseases with a different role of the immune system. 
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Cytotoxic T-cell activation and GrB release can induce apoptosis. Therefore the apoptotic 
signaling cascade plays a major role. Generally, apoptosis can be induced by various triggers and the 
major enzymes in this pathway are caspases. The caspases can be divided in two groups; the 
initatorcaspases, of which caspase-8, -9 and -10 are the most prominent ones and the executioner 
caspases. Caspase-3, -6 and -7 contribute to the last group. If apoptosis is induced, the initatorcaspases 
are cleaved, transform to their active conformation and further activate executioner caspases. These 
enzymes can then cleave target proteins and induce apoptotic cell death (Fan et al., 2005). To check 
the effects of GrB release effort was put into finding out whether there were activated caspases present 
in the tissue. Results of caspase-3 labeling as well as the staining for caspase-6, showed that in PML 
we could not find any evidence that caspase-mediated apoptosis was really induced in the virus 
positive oligodendrocytes. Interestingly,in the past two papers have dealt with the topic of 
oligodendrocyte death, but the from these two publications are rather controversial. Accordingly, a 
convincing explanation for oligodendrocyte death has not yet been found. In one of those papers the 
authors claim, that apoptosis is the underlying mechanism leading to death of virus infected 
oligodendrocytes. As proof for this theory double staining of JC virus containing cells together with a 
TUNEL-staining is given (Richardson-Burns et al., 2002). However, the TUNEL labeling only 
recognizes DNA-double strand breaks which are occurring in both apoptotic as well as necrotic cells 
(Perry et al., ). As such the TUNEL staining is not giving any information on the pathway leading to 
cell death. In addition, the virus replication induces DNA strand breaks themselves and due to this also 
non-dying virus infected cells are recognized by TUNEL. In the second paper it is described that due 
to the virus infection survivin, an anti-apoptotic protein, is newly expressed in the virus containing 
cells and therefore protects those cells of getting killed due to initiation of apoptosis (Pina-Oviedo et 
al., 2007). Although this mechanism may extend the life of infected oligodendrocytes, the enormous 
loss of oligodendrocytes and severe demyelination show that eventually large numbers of these 
oligodendrocytes undergo cell death. Since the authors of these two papers hold an opposite view on 
the topic and since the obtained data showed no evidence that caspase-mediated apoptosis, initiated by 
cytotoxic T cells is involved in the death of oligodendrocytes, it was suggested that another 
mechanism might be involved. A recent paper from our group (Veto et al., 2010) shows that in 
multiple sclerosis (MS) pattern III lesions oligodendrocyte death and demyelination is induced due to 
overactivation of poly(ADP-ribose) polymerase 1(PARP-1) and translocation of apoptosis inducing 
factor (AIF) into the nucleus. It is claimed that due to these events caspase-dependent apoptosis is 
prohibited and that cell death is initiated due to AIF accumulation in the nucleus of oligodendrocytes 
and therefore induces a caspase-independent cell death pathway (Veto et al., 2010). The results of this 
paper were very interesting and give a new explanation for oligodendrocyte death. Therefore it was 
checked whether similar events could be observed in the PML-samples. Staining for PAR, the side 
product of PARP-1, showed that this molecule, that is usually restricted to the nucleus, was widely 
distributed in the cytosol of the virus-infected oligodendrocytes. Furthermore, it was seen that AIF was 
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not restricted to the mitochondria, but was also present in the nucleus. This translocation of AIF to the 
nucleus can induce DNA-fragmentation and is able to lead to cell death. These events described here 
and detected in the PML-samples are the key events of so-called parthanatos. This apoptotic pathway 
is generally said to be independent of caspases and translocation of AIF into the nucleus is handled as 
the commitment point. Nevertheless, at a certain, rather late time point, also caspases get activated, but 
this activation is said to occur in such a late stage, that cell death is not dependent on the function of 
caspases anymore (Yu et al., 2006). 
Of course all these observations were compared between the PML-cases and HSV encephalitis and 
CMV encephalitis cases. The first difference that was found in the comparison of the viral encephalitis 
diseases was that in the CMV cases a very clear double labeling of virus infected cells together with 
activated caspase-3 was present. In addition, we could show a release of caspase-6 from the 
mitochondria into the cytosol. This already made it rather clear that cell death in the CMV-infected 
cells is most likely induced due to caspase-mediated apoptosis. Analysis of the presence of PAR in the 
cytosol and AIF in the nucleus of the virus infected cells showed that infected cells did not have these 
properties. This, and the presence of multiple GrB+ cytotoxic T cells in close apposition to these 
infected cells strongly suggests that in CMV encephalitis, unlike in PML, cytotoxicity by T cells is the 
central mechanism behind the pathogenesis of this disease. Evaluation of data coming from the HSV 
encephalitis diseases, showed that such a clear difference as seen in the comparison of CMV 
encephalitis to PML is not present. Presence of activated caspase was observed in the HSV-samples, 
but in the double labeling for the virus and caspase-3 the frequency for these double labeled cells was 
definitely lower than in the CMV-cases. A possible explanation might be that at the time caspase-3 
activity reaches detectable levels by immunohistochemistry all the viral proteins are used as substrates 
and for the caspases and therefore become undetectable. Alternatively, other mechanisms are involved 
in the pathogenesis of HSV-encephalitis. The pathways leading to cell death however have to be 
different from parthanatos, since the HSV cases were naturally checked for the key events. 
Interestingly, cells containing cytosolic PAR were sometimes detected, but the commitment event of 
AIF translocation towards the nucleus was never observed. Therefore, it was not possible to find cells 
containing the HSV virus, PAR in the cytosol and AIF in the nucleus at the same time. Additionally, 
those cells containing PAR in the cytosol were mainly located in an area of necrosis, so this 
cytoplasmic localization might result from events occurring in those cells due to a deathly insult 
leading to a necrotic form of cell death not involving the PAR/AIF pathway.
To summarize, the results of this study give a convincing explanation on how cell death in 
oligodendrocytes in PML is initiated. This could therefore lead to an end of the discussion if apoptosis 
is occurring in the JC virus infected oligodendrocytes. Whereas in PML encephalitis, T cell 
cytotoxicity is not responsible for the death of infected cells, in CMV encephalitis indeed results 
strongly suggest that CD8+ T cells are involved. In HSV encephalitis moderate numbers of appositions 
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of cytotoxic T cells were found as well as low numbers of caspase-3 positive infected cells, suggesting 
that T cell cytotoxicity plays a role to a certain extend. Still further information needs to be gained on 
cell death in HSV encephalitis in order to be able to interfere in this mechanism to be able to help 
patients to a better outcome. Since it seems to be pretty clear that in CMV encephalitis cell death is 
resulting from apoptosis, possibilities in prevention of apoptosis should form a central topic in 
research. Regarding PML encephalitis research, future efforts should be put in gaining information on
the exact events happening during parthanatos. The central question here should be if there is a 
possible chance to interfere in this pathway in order to stop oligodendrocytes from being killed. 
Naturally, this knowledge should then be used for therapy development to improve treatment of this 
disease. 
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7. Abbreviations used
AB antibody
ABC avidin biotin comlex
AEC 3-amino-9-ethyl-carbazole
AG antigen
AIDS acquired immune deficiency syndrome
AIF Apoptosis inducing factor
AP alkaline phosphatase
bi biotinylated
Bid BH3-interacting death agonist
CAII Carbonic anhydrase II
Casp-6 Caspase 6
CMV cytomegalovirus
CNPase 2', 3'-cyclic nucleotide 3'-phosphodiesterase
CNS central nervous system
CSA catalyzed signal amplification system
CTL cytotoxic t-lymphocytes
Cy2 Cyanine 2 (Dye)
DAB 3,3-diaminobenzidine tetrahydrochloride hydrate
Dapi 4’,6’-diamidino-2-phenylindole
DMF dimethylformamid
DNA deoxyribonucleic acid
EDTA ethylenediaminetetraacetic acid
Abbreviations used
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FB diazonium salt fast blue
FCS fetal calve serum
GFAP glial fibrillary acidic protein
GrB Granzyme B
HE Hematoxylin-Eosin
HIV human immunodeficiency virus
HRP Horse radish peroxidase
HSV herpes simplex virus
IgG (H+L) Immunglobulin G (heavy and light chain)
IHC immunhistochemistry
IRIS immune reconstitution inflammatory syndrome
JC virus John Cunningham virus
JCV John Cunningham virus
KL Klüver-Barrera
LAMP lysosome associated membrane protein
LM light microscopy
mAb monoclonal antibody
MHC major histochompatibility complex
NAD nicotineamide adenine dinucleotide
NCCR noncoding control region
NK-cell natural killer cell
ORI origin of replication
PAR poly (ADP-ribose)
PARP poly (ADP-ribose) polymerase
PAS perjodic acid Schiff stain
Abbreviations used
61
PBS Phosphate buffered saline
PML progressive multifocal leukoencephalopathy
SOCC store operated calcium channel
SV40 simian virus 40
tBid truncated Bid
TBS Tris buffered saline
TCR T-cell receptor
TPPP tubulin polymerization promoting protein
VP1 viral protein 1
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